US20090142410A1 - Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise - Google Patents

Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise Download PDF

Info

Publication number
US20090142410A1
US20090142410A1 US12/291,482 US29148208A US2009142410A1 US 20090142410 A1 US20090142410 A1 US 20090142410A1 US 29148208 A US29148208 A US 29148208A US 2009142410 A1 US2009142410 A1 US 2009142410A1
Authority
US
United States
Prior art keywords
increasing
creatine
dietary supplement
phosphate
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/291,482
Inventor
Marvin A. Heuer
Kenneth Clement
Shan Chaudhuri
James D. Ramsbottom
Megan K. Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US12/291,482 priority Critical patent/US20090142410A1/en
Publication of US20090142410A1 publication Critical patent/US20090142410A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/76—Salicaceae (Willow family), e.g. poplar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L29/00—Semiconductor devices adapted for rectifying, amplifying, oscillating or switching, or capacitors or resistors with at least one potential-jump barrier or surface barrier, e.g. PN junction depletion layer or carrier concentration layer; Details of semiconductor bodies or of electrodes thereof  ; Multistep manufacturing processes therefor
    • H01L29/40—Electrodes ; Multistep manufacturing processes therefor
    • H01L29/401—Multistep manufacturing processes
    • H01L29/4011—Multistep manufacturing processes for data storage electrodes
    • H01L29/40114—Multistep manufacturing processes for data storage electrodes the electrodes comprising a conductor-insulator-conductor-insulator-semiconductor structure
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L29/00—Semiconductor devices adapted for rectifying, amplifying, oscillating or switching, or capacitors or resistors with at least one potential-jump barrier or surface barrier, e.g. PN junction depletion layer or carrier concentration layer; Details of semiconductor bodies or of electrodes thereof  ; Multistep manufacturing processes therefor
    • H01L29/40—Electrodes ; Multistep manufacturing processes therefor
    • H01L29/41—Electrodes ; Multistep manufacturing processes therefor characterised by their shape, relative sizes or dispositions
    • H01L29/423—Electrodes ; Multistep manufacturing processes therefor characterised by their shape, relative sizes or dispositions not carrying the current to be rectified, amplified or switched
    • H01L29/42312—Gate electrodes for field effect devices
    • H01L29/42316—Gate electrodes for field effect devices for field-effect transistors
    • H01L29/4232—Gate electrodes for field effect devices for field-effect transistors with insulated gate
    • H01L29/42324—Gate electrodes for transistors with a floating gate
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L29/00—Semiconductor devices adapted for rectifying, amplifying, oscillating or switching, or capacitors or resistors with at least one potential-jump barrier or surface barrier, e.g. PN junction depletion layer or carrier concentration layer; Details of semiconductor bodies or of electrodes thereof  ; Multistep manufacturing processes therefor
    • H01L29/66—Types of semiconductor device ; Multistep manufacturing processes therefor
    • H01L29/68—Types of semiconductor device ; Multistep manufacturing processes therefor controllable by only the electric current supplied, or only the electric potential applied, to an electrode which does not carry the current to be rectified, amplified or switched
    • H01L29/76—Unipolar devices, e.g. field effect transistors
    • H01L29/772—Field effect transistors
    • H01L29/78—Field effect transistors with field effect produced by an insulated gate
    • H01L29/788—Field effect transistors with field effect produced by an insulated gate with floating gate
    • H01L29/7881—Programmable transistors with only two possible levels of programmation
    • H01L29/7884—Programmable transistors with only two possible levels of programmation charging by hot carrier injection
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L29/00—Semiconductor devices adapted for rectifying, amplifying, oscillating or switching, or capacitors or resistors with at least one potential-jump barrier or surface barrier, e.g. PN junction depletion layer or carrier concentration layer; Details of semiconductor bodies or of electrodes thereof  ; Multistep manufacturing processes therefor
    • H01L29/66—Types of semiconductor device ; Multistep manufacturing processes therefor
    • H01L29/68—Types of semiconductor device ; Multistep manufacturing processes therefor controllable by only the electric current supplied, or only the electric potential applied, to an electrode which does not carry the current to be rectified, amplified or switched
    • H01L29/76—Unipolar devices, e.g. field effect transistors
    • H01L29/772—Field effect transistors
    • H01L29/78—Field effect transistors with field effect produced by an insulated gate
    • H01L29/788—Field effect transistors with field effect produced by an insulated gate with floating gate

Definitions

  • the present invention relates to the composition of a dietary supplement provided for increasing Creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and aiding in recovery following exercise as well as providing support for the immune system during intense periods of exercise.
  • compositions and methods which minimize catabolism and promote muscle anabolism, particularly in response to exercise.
  • the compositions and methods may allow an individual to increase muscle size, strength or endurance training as well as reduce recovery time and facilitate an increased training volume leading to the same.
  • compositions and methods which comprise at least a combination of Creatine or derivatives thereof, Taurine or derivatives thereof and a source of Phosphate.
  • compositions and methods that further comprise at least one of Double Fermented Triticum aestivum , Dextrose, Isomalt, Trehalose, D-Mannose, an extract of Mulberry, Enicostemma littorale Blume, Scoparia dulcis , an extract of Tarragon, Andrographis paniculata , Chromium or derivatives thereof, Glutamine and Alpha Lipoic Acid.
  • the present invention is directed to a dietary supplement for increasing Creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and aiding in post-exercise recovery as well as providing support for the immune system during intense exercise training periods.
  • the present invention comprises at least a source of Creatine or derivative thereof, Taurine or derivative thereof and a source of Phosphate.
  • the present invention may further comprise combinations of Double Fermented Triticum aestivum , Dextrose, Isomalt, Trehalose, D-Mannose, an extract of Mulberry, Enicostemma littorale Blume, Scoparia dulcis , an extract of Tarragon, Andrographis paniculata , Chromium or derivatives thereof, Glutamine and Alpha Lipoic Acid.
  • the term “derivative” refers to a compound, such as a salt, ester, or amine, which can readily supply a closely related biologically active compound, either upon administration or upon exposure to specific environmental conditions, such as pH, temperature, etc.
  • a “derivative” of creatine can be a salt, ester or amine of creatine, so long as the derivative can readily supply biologically active creatine.
  • the skilled person in the art will readily recognize and envisage those closely related compounds which should be considered “derivatives.”
  • a derivative of a particular substance may comprise a form of that substance which has been modified through reaction.
  • Other derivatives are forms of a given substance that are precursors of that substance which would give rise to that substance after modification. Reactions involved in the formation of derivatives include, but are not limited to: hydroxylation, esterification, amide formation and salt formation.
  • Carbohydrate refers to at least a source of carbohydrates such as, but not limited to, monosaccharides, disaccharides, oligosaccharides, polysaccharides or derivatives thereof.
  • Creatine refers to the chemical N-methyl-N-guanyl Glycine, (CAS Registry No. 57-00-1), also known as, (alpha-methyl guanido) acetic acid, N-(aminoiminomethyl)-N-glycine, Methylglycocyamine, Methylguanidoacetic Acid, or N-Methyl-N-guanylglycine. Additionally, as used herein, “Creatine” also includes derivatives of Creatine such as esters, and amides, and salts, as well as other derivatives, including derivatives that become active upon metabolism. Furthermore, Creatinol (CAS Registry No.
  • Creatine-O-Phosphate N-methyl-N-(beta-hydroxyethyl)guanidine O-Phosphate, Aplodan, or 2-(carbamimidoyl-methyl-amino)ethoxyphosphonic acid, is henceforth in this disclosure considered to be a Creatine derivative.
  • Phosphate refers to at least a source of Phosphate ions such as, but not limited to, Dipotassium Phosphate, Disodium Phosphate, Magnesium Phosphate or derivatives thereof.
  • Carbohydrate ingestion is known to stimulate the secretion of insulin which in turn facilitates the uptake of glucose into skeletal muscle via glucose transporter 4 (GLUT4) translocation (Wang et al., J Cell Biol. 1996 135:415-30).
  • Glucose is then converted to and stored as glycogen and triglycerides. Concomitant with this, insulin inhibits the release and synthesis of glucose (Khan et al., Diabetologia. 2002 45:1475-83).
  • insulin also plays an important role in protein metabolism where it inhibits the breakdown of protein or proteolysis (Volpi E and Wolfe B. In: Handbook of Physiology, L. Jefferson and A. Cherrington (eds.) New York: Oxford, 2001, p.
  • Creatine retention As compared to Creatine and carbohydrate alone is significantly improved (Burke et al., Int J Sport Nutr Exerc Metab. 2003 13:294-302). Therefore, it is deemed to be advantageous, that for the purposes of Creatine retention, the actions of insulin be enhanced. Furthermore, it may be advantageous to increase the activity and availability of Creatine in skeletal muscle.
  • Combinations comprising some of the aforementioned ingredients have been shown to offer further benefit to muscle building and increasing strength.
  • 32 males were divided into four groups of eight subjects.
  • Group 1 received a combination of Creatine/Dextrose/Taurine/Alpha Lipoic Acid
  • Group 2 received Creatine plus grape juice
  • Group 3 received Creatine plus water
  • group 4 a placebo.
  • Group 1 had demonstrated greater improvements in body composition and muscular endurance as compared to the other three groups (Kalman et al., Med Sci Sports Exerc. 2000, 32, Supplement abstract 562).
  • Creatine/Dextrose/Alpha Lipoic Acid was found to provide improved results versus supplementation with whey protein alone in terms of muscle mass gain (Kalman et al., FASEB. 2000, 14:A619).
  • an eight week study which included diet and weight training subjects consuming a combination comprising Creatine/Dextrose/Taurine/Ascorbic Acid/Chromium/Alpha Lipoic Acid/Phosphorus gained significantly more mass than subjects consuming Protein/Dextrose alone (Tamopolsky et al., Med Sci Sports Exerc. 2001 33(:2044-52).
  • the activity of insulin initiated by the ingestion of carbohydrates, such as Dextrose as comprised in the present invention can be enhanced and sustained by insulin potentiators such as, including but not limited to, Taurine, Alpha Lipoic Acid, an extract of Mulberry, Chromium, Glutamine, Enicostemma littorale Blume, Scoparia dulcis , an extract of Tarragon and Andrographis paniculata .
  • the present invention may comprise one or more of Isomalt, Trehalose or D-Mannose to further potentiate the secretion or activity of insulin.
  • the enhanced activity of insulin may facilitate increased uptake and retention of Creatine, as incorporated into the present invention, by skeletal muscle.
  • Creatine retention may facilitate increased muscle growth, increased muscle endurance and reduced post-exercise recovery time by virtue of the biological role of Creatine.
  • the biological role of Creatine may be aided by ensuring adequate Phosphate availability by the addition of supplemental Phosphates.
  • Creatine is a naturally occurring amino acid derived from the amino acids glycine, arginine, and methionine. Although it is found in meat and fish, it is also synthesized by humans. Creatine is predominantly used as a fuel source in muscle. About 65% of Creatine is stored in muscle as Phosphocreatine (Creatine bound to a Phosphate molecule) (Casey et al., Am J. Physiol. 1996 271:E38-43).
  • Muscular contractions are fueled by the dephosphorylation of adenosine triphosphate (ATP) to produce adenosine diphosphate (ADP) and without a mechanism to replenish ATP stores, the supply of ATP would be totally consumed in 1-2 seconds (Casey and Greenhaff, Am J Clin Nutr. 2000 72:607 S-17S).
  • Phosphocreatine serves as a major source of Phosphate from which ADP is regenerated to ATP.
  • muscular concentrations of Phosphocreatine drop by almost 50% (Gaitanos et al., J Appl Physiol. 1993 75:712-9).
  • Creatine supplementation has been shown to increase the concentration of Creatine in the muscle (Harris et al., Clin Sci (Lond). 1992 83:367-74) and further said supplementation enables an increase in the resynthesis of Phosphocreatine (Greenhaff et al., Am J. Physiol. 1994 266:E725-30) leading to a rapid replenishment of ATP within the first two minutes following the commencement of exercise.
  • Creatine can improve strength and reduce fatigue (Greenhaff et al., Clin Sci (Lond). 1993 84:565-71). Resistance training with supplemented creatine experiments display a result of increased strength and fat-free mass over a placebo in sedentary females (Vandenberghe et al., J Appl Physiol. 1997 83:2055-63) and in male football players (Vandenberghe et al., J Appl Physiol. 1997 83:2055-63). In addition to increasing fat-free mass and strength, Creatine supplementation increases muscle fiber cross sectional area (Volek et al., Med Sci Sports Exerc. 1999 31:1147-56) thereby increasing muscle volume.
  • Creatine supplementation may also benefit individuals with muscle dystrophy disorders by reducing muscle loss (Walter et al., Neurology. 2000 54:1848-50).
  • Creatine may have antioxidant properties (Lawler et al., Biochem Biophys Res Commun. 2002 290:47-52; Sestili et al., Free Radic Biol Med. 2006 40:837-49).
  • the antioxidant activity of Creatine may additionally aid post-exercise muscle recovery.
  • Creatine retention has been shown to be markedly improved by the concomitant ingestion with carbohydrates, up to 60% better, which may further be related to increased insulin concentration (Green et al., Am J. Physiol. 1996 271:E821-6). Furthermore, glucose and Creatine uptake by muscle cells has been shown to be stimulated by insulin (Odoom et al., Mol Cell Biochem. 1996 158:179-88). Thus, the ingestion of Creatine combined with a source of carbohydrates is recommended to improve retention. It may also be beneficial to include a source of protein at the time of Creatine ingestion (Steenge et al., J Appl Physiol. 2000 89:1165-71).
  • U.S. Pat. No. 5,767,159 purports to describe a method for increasing muscle capacity and replenishing ATP by administering daily Creatine in healthy mammals.
  • the amount of said Creatine is at least 0.2-0.4 g per kg body weight and not less than 15 g in a 70 kg mammal to be taken for at least 2 days but not more than 7 days.
  • the Creatine is administered in solution which may further include other conventional nutrients such as lipids, carbohydrates, amino acids, electrolytes, trace elements and vitamins.
  • U.S. Pat. No. 5,968,544 purports to describe compositions containing Creatine for human consumption suitable for use in a drink or as dry powder stable for storage.
  • the Creatine is provided in an acidic yogurt-based semi-liquid composition or forms an acidic solution when mixed with water.
  • compositions described are composed of Creatine or Creatine derivatives with a carbohydrate, wherein the carbohydrate is said to cause an increase in blood plasma insulin levels, which results in increases in Creatine retention.
  • the dietary supplement includes Creatine or derivatives thereof.
  • a serving of the dietary supplement may include from about 3 g to about 15 g of Creatine or derivatives thereof.
  • the preferred dosage of a serving of the dietary supplement comprises about 10 g of Creatine or derivatives thereof.
  • Taurine an amino acid found primarily in nerve and muscle tissue, is generally considered to be a conditionally-essential amino acid, being only required under certain circumstances. As it is not utilized for protein synthesis, Taurine is found in the free form or in some small peptides. The accumulation of Taurine within cells is mediated via a high affinity sodium-dependent transporter (Ramamoorthy et al., Biochem J. 1994 300:893-900). The expression of this Taurine transporter is induced by differentiation program of myocytes (muscle cells) (Uozumi et al., Biochem J. 2006 394:699-706). Exercise-induced hormones also known to activate the Taurine transporter (Park et al., Biofactors. 2004 21:403-6). Moreover, genetically modified mice lacking the Taurine transporter have depleted Taurine levels in all muscle and have impaired skeletal muscle function (Warskulat et al., FASEB J. 2004 18:577-9)
  • Taurine has also been shown to modulate the contractile function of mammalian skeletal muscle (Bakker et al., J. Physiol. 2002 538:185-94). In rats, the Taurine concentration in muscle decreases as a result of exercise (Matsuzaki et al., Med Sci Sports Exerc. 2002 34:793-7) and oral supplementation with Taurine has been shown to maintain the concentration of Taurine in muscle and prolong exercise performance (Miyazaki et al., Amino Acids. 2004 27:291-8; Yatabe et al., J Orthop Sci. 2003; 8:415-9).
  • Taurine supplementation has been shown to improve insulin sensitivity in rats (Nakaya et al., Am J Clin Nutr. 2000 71:54-8). Furthermore, Taurine improves glucose metabolism in insulin resistant rats (Nandhini et al., Amino Acids. 2002; 22:27-38), suggesting that Taurine has insulin-like properties which may improve Creatine uptake and retention within muscle cells. Supplementation with Taurine has additionally been shown to reduce exercise-induced oxidative damage and enhance recovery (Zhang et al., Amino Acids. 2004 26:203-7).
  • the dietary supplement includes Taurine or derivatives thereof.
  • a serving of the dietary supplement may include from about 0.5 g to about 3 g of Taurine or derivatives thereof.
  • the preferred dosage of a serving of the dietary supplement comprises about 2.1 g of Taurine or derivatives thereof.
  • Phosphate or phosphorus
  • Phosphate salt with calcium Phosphate is involved in the formation of bone and teeth. In other salt complexes, Phosphate is involved in acid-base balance. Phosphate is also important for the structures of DNA and cell membranes. One of the most important roles of Phosphate is energy production in muscle as ATP and Phosphocreatine. Phosphate is also part of a compound in red blood cells known as 2,3 DPG (2,3-diphosphoglycerate), which facilitates the release of oxygen to the muscle tissues.
  • 2,3 DPG 2,3 DPG (2,3-diphosphoglycerate
  • Supplemental Phosphate salts have been shown to increase the concentration of 2,3 DPG in red blood cells, increasing VO2 max (a measure of aerobic fitness) and a reduction in the production of lactate (Cade et al., Med Sci Sports Exerc. 1984 16:263-8). Moreover, Phosphate has also been shown to enhance oxygen uptake and run performance without affecting the level of 2,3 DPG (Kreider et al., Med Sci Sports Exerc. 1990 22:250-6).
  • the metabolic rate can also be increased by Phosphate supplementation (Nazar et al., J Physiol Pharmacol. 1996 47:373-83).
  • the dietary supplement includes a source of Phosphate or derivatives thereof.
  • a serving of the dietary supplement may include from about 0.1 g to about 1.5 g of Phosphate or derivatives thereof.
  • the preferred dosage of a serving of the dietary supplement comprises about 0.18 g of elemental Phosphate or derivatives thereof.
  • Alpha Lipoic Acid is an enzyme found in the cellular energy-producing structures, the mitochondria. ALA works in synergy with vitamins C and E as an antioxidant in both the water- and fat-soluble environments.
  • ALA appears to possess a dual action related to hunger and >oxidation of fat.
  • the activity of AMP-activated protein kinase which acts as an energy sensor in the hypothalamus, is reduced by ALA in rodents, this results in a profound weight loss by reducing food intake and enhancing energy expenditure (Kim et al., Nat Med. 2004 10:727-33).
  • ALA increases Uncoupling Protein-1 in rodent adipocytes while increasing AMP-activated protein kinase in skeletal muscle cells and increasing glucose uptake and energy expenditure (Lee et al., Int J Biochem Cell Biol. 2005 37:2254-9). Therefore, ALA seemingly has different effects in different tissues.
  • ALA increases fatty acid oxidation, leading to an increase in energy expenditure and a decrease in weight and food intake.
  • U.S. Pat. Nos. 6,136,339 and 6,620,425 disclose compositions and methods for enhancing an athlete's muscle size or strength using a combination of Creatine, Alpha Lipoic Acid and optionally Dextrose, to be taken mixed with water daily following exercise.
  • the dietary supplement may include Alpha Lipoic Acid or derivatives thereof.
  • a serving of the dietary supplement may include from about 0.005 g to about 0.4 g of Alpha Lipoic Acid or derivatives thereof.
  • the preferred dosage of a serving of the dietary supplement comprises about 0.25 g of Alpha Lipoic Acid or derivatives thereof.
  • Dextrose is a simple sugar or monosaccharide commonly known as D-glucose. Also known as ‘grape sugar’ or ‘blood sugar’, it is found mainly in honey and fruits and is a building-block of glycogen, cellulose and starch. Recently, Dextrose was shown to boost the performance a female rowers as compared to ribose, which had been theorized to replenish muscle energy (Dunne et al., Clin J Sport Med. 2006 16:68-71).
  • the dietary supplement may include Dextrose.
  • a serving of the dietary supplement may include from about 50 g to about 100 g of Dextrose.
  • the preferred dosage of a serving of the dietary supplement comprises about 75 g of Dextrose.
  • Mulberry ( Morus alba ) is an edible plant used in Chinese medicine which is rich in flavonoids possessing antioxidant activity (Doi et al. Chem Pharm Bull (Tokyo). 2001 49:151-3). Orally administered mulberry extracts of Mulberry reduced blood glucose levels of both non-diabetic and streptozotocin-treated diabetic rats, commensurate with decreased food intake (Musabayane et al., Methods Find Exp Clin Pharmacol. 2006 28:223-8). Orally consumed extracts of Mulberry have also been shown to inhibit increases in blood glucose resulting from the ingestion of carbohydrates such as sucrose in humans and rats (Oku et al., Br J. Nutr. 2006 95:933-8).
  • extracts of Mulberry confer neuroprotective benefits (Kang et al., Biol Pharm Bull. 2006 29:270-4) and may further attenuate the development of atherosclerotic lesions (Enkhmaa et al., J. Nutr. 2005 135:729-34).
  • the dietary supplement may include Mulberry extract.
  • a serving of the dietary supplement may include from about 0.01 g to about 0.05 g of Mulberry extract.
  • the preferred dosage of a serving of the dietary supplement comprises about 0.025 g of Mulberry extract.
  • Chromium is an essential trace mineral that is used to control blood sugar levels by aiding insulin, which can help control or reduce weight. Chromium is poorly absorbed by the body and must therefore be combined with a more efficiently absorbed compound such as niacin as in the case of polynicotinate. Chromium likely exerts its main function as a component or a co-factor of the glucose tolerance factor, which is involved in insulin sensitivity.
  • Chromium has been shown clinically to increase lean mass (Bahadori et al., Acta Med Austriaca. 1997 24:185-7) and reduce body fat when combined with exercise (Grant et al., Med Sci Sports Exerc. 1997 29:992-8). Moreover, chromium has also been shown to increase high density lipoproteins (HDL i.e. ‘good’ cholesterol) (Riales et al., Am J Clin Nutr 1981; 34:2670-8). Numerous clinical studies have demonstrated the relationship between supplemental Chromium and improved insulin activity and glucose metabolism (Anderson, Diabetes Metab. 2000 26:22-7).
  • the dietary supplement may include a derivative of Chromium.
  • a serving of the dietary supplement may include from about 0.001 g to about 0.005 g of a derivative of Chromium.
  • the preferred dosage of a serving of the dietary supplement comprises about 0.003 g of a derivative of Chromium.
  • Glutamine is the most abundant amino acid found in muscle and has important functions as a precursor for the synthesis of other amino acids. Many cells required for immune function rely on Glutamine as source for energy production.
  • Glutamine is often considered to be a ‘conditionally essential’ amino acid.
  • this depletion of Glutamine has been linked to immunosuppression often resulting from intense training (Newsholme, Int J Sports Med. 1994 15:S142-7).
  • Supplementation with Glutamine in conjunction with additional antioxidants can increase body weight, body cell mass and intracellular water when compared with placebo (Shabert et al., Nutrition. 1999 15:860-4).
  • Glutamine is also capable of stimulating insulin secretion (Tanizawa et al., Diabetes. 2002 51:712-7).
  • the dietary supplement may include Glutamine or a derivative thereof.
  • a serving of the dietary supplement may include from about 0.001 g to about 0.005 g of Glutamine or a derivative thereof.
  • the preferred dosage of a serving of the dietary supplement comprises about 0.002 g of Glutamine or a derivative thereof.
  • Enicostemma littorale Blume is a flower-producing herb found in South America, Africa, and Asia. In rat models of diabetes, Enicostemma littorale extract can enhance glucose-induced insulin release thereby effectively lowering blood glucose levels (Maroo et al., J. Ethnopharmacol. 2002 81:317-20; Maroo et al., Phytomedicine. 2003 10:196-9).
  • Enicostemma littorale extract counters the changes in several metabolic enzymes and antioxidants observed in diabetic rats, including lowering thiobarbituric acid reactive substances and lipid hydroperoxides while increasing the concentration of reduced glutathione and the activities of superoxide dismutase and catalase (Srinivasan et al., J Pharm Pharmacol. 2005 57:497-503).
  • the lipid profile of rats fed cholesterol was also improved by administration of Enicostemma littorale extract (Vasu et al., J. Ethnopharmacol. 2005 101:277-82).
  • the dietary supplement may include Enicostemma littorale Blume.
  • a serving of the dietary supplement may include from about 0.0005 g to about 0.003 g of Enicostemma littorale Blume.
  • the preferred dosage of a serving of the dietary supplement comprises about 0.001 g of Enicostemma littorale Blume.
  • Scoparia dulcis (Scotch brum)
  • Scoparia dulcis is a tropical herb found in abundance in South America and the Amazon rainforest and has been used traditionally for multiple treatments including diabetes. Extracts of Scoparia dulcis provide both antidiabetic and antihyperlipidemic actions in normal and experimentally diabetic rats (Pari and Latha, J Med Food. 2006 9:102-7). Scoparia dulcis extract has also demonstrated antioxidant and neuroprotective activity (Pari and Latha, BMC Complement Altem Med. 2004 4:16).
  • the dietary supplement may include Scoparia dulcis .
  • a serving of the dietary supplement may include from about 0.0005 g to about 0.003 g of Scoparia dulcis .
  • the preferred dosage of a serving of the dietary supplement comprises about 0.001 g of Scoparia dulcis.
  • Tarragon extract Artemisia dracunculus
  • Russian Tarragon ( Artemisia dracunculus ) is a perennial herb widely used in cooking. Historically, it has been used as a natural blood cleanser and as a treatment for headaches and dizziness. Current studies are examining the use of an ethanolic extract of Russian Tarragon for the treatment of hyperglycemia associated with diabetes. The toxicology of this extract has been evaluated, and has been shown to be safe and non-toxic (Ribnicky et al., Food Chem Toxicol. 2004 42:585-98). Essential oil extracted from Artemisia dracunculus may also have potential as an anticonvulsant and as a mild sedative (Sayyah et al., J. Ethnopharmacol. 2004 94:283-7).
  • the dietary supplement may include Tarragon extract.
  • a serving of the dietary supplement may include from about 0.0005 g to about 0.003 g of Tarragon extract.
  • the preferred dosage of a serving of the dietary supplement comprises about 0.001 g of Tarragon extract.
  • Andrographis paniculata is a medicinal herb used traditionally throughout Asia to treat a number of conditions. Clinical studies have demonstrated an immunity-enhancing benefit of Andrographis paniculata supplementation by reducing the occurrence and severity of common cold symptoms (Caceres et al., Phytomedicine. 1999 6:217-23) and upper-respiratory tract infections (Melchior et al., Phytomedicine. 2000 7:341-50).
  • Andrographis paniculata has been shown to possess antipyretic, fever-reducing, activity similar to that of aspirin (Vedavathy and Rao, J. Ethnopharmacol. 1991 33:193-6). Furthermore, Andrographis paniculata has been shown to reduce chemically-induced liver toxicity in experimental mice (Kapil et al., Biochem Pharmacol. 1993 46:182-5).
  • Andrographis paniculata extract possesses antihyperglycaemic and antioxidative activities in both normal and chemically-induced diabetic rats (Zhang and Tan, Clin Exp Pharmacol Physiol. 2000 27:358-63).
  • the antidiabetic properties of Andrographis paniculata are believed to be due at least in part to enhanced glucose metabolism (Zhang and Tan, Acta Pharmacol Sin. 2000 21:1157-64).
  • the dietary supplement may include Andrographis paniculata .
  • a serving of the dietary supplement may include from about 0.0005 g to about 0.003 g of Andrographis paniculata .
  • the preferred dosage of a serving of the dietary supplement comprises about 0.001 g of Andrographis paniculata.
  • Double Fermented Triticum aestivum is a whole-grain wheat product low in simple sugars and high in complex carbohydrates. This produces a more level glucose/insulin response rather than the typical “spike” resulting from simple sugar ingestion. As such, Double Fermented Triticum aestivum is marketed towards overweight or obese individuals or individuals with impaired glucose tolerance. Double Fermented Triticum aestivum was found effective at reducing the risks associated with development of type 2 diabetes such as elevated fasting blood glucose levels and obesity (Rave et al., 65 th Annual Scientific Sessions, American Diabetes Association 2005, Abstract 1765-P).
  • the dietary supplement may include Double Fermented Triticum aestivum .
  • a serving of the dietary supplement may include from about 0.05 g to about 0.3 g of Double Fermented Triticum aestivum .
  • the preferred dosage of a serving of the dietary supplement comprises about 0.1 g of Double Fermented Triticum aestivum.
  • Isomalt is a disaccharide sugar substitute derived from sucrose which is less sweet than, and is often mixed with, more conventional sweeteners. Being only partially digested in the intestines, isomalt results in a low blood glucose effect, has benefits similar to that of dietary fiber, and has a caloric value of about half that of sugar. Moreover, Isomalt has been shown to promote healthy bowel function without impairing metabolic function (Gostner et al., Br J. Nutr. 2005 94:575-81; Gostner et al. Br J. Nutr. 2006 95:40-50).
  • the dietary supplement may include Isomalt.
  • a serving of the dietary supplement may include from about 0.0005 g to about 0.003 g of Isomalt.
  • the preferred dosage of a serving of the dietary supplement comprises about 0.001 g of Isomalt.
  • Trehalose is a naturally occurring disaccharide found in plants, invertebrates and fungi and is about half as sweet as sucrose or table sugar. Trehalose has been discovered to be able to inhibit the aggregation of some proteins and thus has potential in the prevention of diseases linked to such events such as Huntington's disease (Tanaka et al., Nat Med. 2004 10:148-54).
  • the dietary supplement may include Trehalose.
  • a serving of the dietary supplement may include from about 0.0005 g to about 0.003 g of Trehalose.
  • the preferred dosage of a serving of the dietary supplement comprises about 0.001 g of Trehalose.
  • Mannose is a monosaccharide found in some fruits including cranberry. It is absorbed slowly in the gastrointestinal tract, with most being excreted in the urine. D-mannose has been theorized to aid in the treatment of urinary tract infections by virtue of being able to bind to the surface proteins of infection-causing bacteria, thereby facilitating their clearance (Schaeffer et al., J. Urol. 1984 131:906-10).
  • the dietary supplement may include D-mannose.
  • a serving of the dietary supplement may include from about 0.0005 g to about 0.003 g of D-mannose.
  • the preferred dosage of a serving of the dietary supplement comprises about 0.001 g of D-mannose.
  • the dietary supplement may be consumed in any form.
  • the dosage form of the dietary supplement may be provided as, e.g., a powder beverage mix, a liquid beverage, a ready-to-eat bar or drink product, a capsule, a liquid capsule, a tablet, a caplet, or as a dietary gel.
  • the preferred dosage form of the present invention is as a powder beverage mix or a drink product.
  • the dosage form of the dietary supplement in accordance with the example embodiments set forth below, may be provided in accordance with customary processing techniques for herbal and/or dietary supplements, wherein the active ingredients are suitably processed into a desired form.
  • one or more ingredients of the diet supplement are processed so as to form fine-milled particles.
  • one or more ingredients of the dietary supplemental are processed by a large-scale dry milling technique that produces fine particles, preferably known as fine-milled particles.
  • fine-milled particles for the purpose of providing the one or more ingredients in particle sizes that optimize one or more of the flow and dispersability, stability, resistance to moisture, bioavailability, and dissolution/release properties of the one or more ingredients in a dietary supplement.
  • In vitro tests designed to simulate the environment of stomach were preformed to test the dissolution rate of fine-milled particle tablets versus non-fine-milled. These test showed that in tablets produced from fine-milled particles the time to 100% dissolution was approximately 15 minutes. In the case of non-fine-milled particle compositions, only 90% dissolution was observed after 120 minutes.
  • the dietary supplemental contains fine-milled particles having and average size between about 50 nm and about 2 nm.
  • U.S. Provisional Patent Application 60/776,325 discloses a method for improving the absorption, palatability, taste, texture, and bioavailability of compounds by increasing the solubility of said compounds in proprietary formulations for the purposes of enhancing or improving muscle size, growth and/or recovery time and/or weight loss.
  • the increased bioavailability of the compound or ingredients is achieved by reducing the particle size via “fine-milling” thereby increasing the surface area-to-volume ratio each particle, thus increasing the rate of dissolution.
  • the compositions and methods disclosed promote increased bioavailability by increasing the total surface area of poorly soluble particles, thereby increasing the rate of absorption.
  • fine-milled and/or “fine-milling” refers to the process of micronization.
  • Micronization is a mechanical process that involves the application of force to a particle, thereby resulting in a reduction in the size of the particle.
  • the force in the case of micronization may be applied in any manner such as, e.g., the collision of particles at high rates of speed, grinding, or by an air-jet micronizer.
  • fine-milled particles are obtained by jet-milling with nitrogen and compressed air.
  • particle size refers to the diameter of the particle.
  • average particle size means that at least 50% of the particles in a sample will have the specified particle size.
  • at least 80% of the particles in a sample will have the specified particle size, and more preferably, at least 90% of the particles in a given sample will have the specified particle size.
  • the size of a particle can be determined any of the methods known within the art. Methods for particle size determination which may be employed are for example, e.g., sieves, sedimentation, electrozone sensing (Coulter counter), microscopy, and/or Low Angle Laser Light Scattering.
  • the preferred methods for the particle size determination of the present invention are those methods which are most commonly used in the pharmaceutical industry, such as laser diffraction, e.g., via light scattering Coulter Delsa 440SX.
  • the fine-milling process may be employed in the processing of one or more of the ingredients of the present invention in the dosage forms of tablets, e.g., immediate-release film coated, modified-release and fast-dissolving; capsules or tablets, e.g., immediate-release and modified-release; liquid dispersions; powders; drink mixes, etc.
  • tablets e.g., immediate-release film coated, modified-release and fast-dissolving
  • capsules or tablets e.g., immediate-release and modified-release
  • liquid dispersions powders; drink mixes, etc.
  • the dietary supplement of the present invention is consumed by an individual in accordance with the following method:
  • a serving of said dietary supplement may be taken by means of mixing in about 360-450 ml of an acceptable aqueous fluid at least one (1) time daily wherein each serving is comprised of two (2) scoops comprising about 100 g total mass of the dietary supplement.
  • Said dietary supplement may be consumed approximately 0 to 60 minutes following a workout, or in the morning upon waking on non-workout days.
  • the dietary supplement may increase Creatine uptake and retention in skeletal muscle, increase muscle mass and strength, increase exercise capacity and aid in post-exercise recovery as well as provide support for the immune system during intense exercise training periods
  • the dosage form of the supplemental composition may be provided in accordance with customary processing techniques for herbal and dietary supplements in any of the forms mentioned above.
  • the dietary supplement set forth in the example embodiments herein may contain any appropriate number and type of excipients, as is well-known in the art.
  • the present dietary supplement or those similarly envisioned by one of skill in the art may be utilized in compositions and methods for increasing Creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and aiding in post-exercise recovery as well as providing support for the immune system during intense exercise training periods of an individual, e.g. a human or an animal in a formulation designed to be consumed at least one time per day.
  • a serving of the dietary supplement comprises the following ingredients in powdered beverage mix form.
  • the dietary supplement comprises for example: about 74 g of pharma grade Dextrose 99 DE, about 9 g of Creatine monohydrate, finely grinded, about 2.1 g of Taurine, about 0.33 g of Dipotassium Phosphate, about 0.33 g of Magnesium Phosphate, about 0.26 g of Sodium Alpha Lipoic Acid, about 0.025 g of and extract of Mulberry, about 0.003 g of Chromium polynicotinate, about 0.001 g of Anhydrous Creatine, about 0.001 g of Taurine ethyl ester HCl, about 0.001 g of Glutamine AKG 2:1, about 0.001 g of Glutamine ethyl ester HCl, about 0.001 g of Enicostemma littorale Blume, about 0.001 g of Scoparia dulcis , about 0.001
  • a dietary supplement As a dietary supplement, 2 scoops, comprising about 100 g total mass of the dietary supplement are administered by a means of mixing said dietary supplement in 360-450 ml of an acceptable aqueous fluid at least one (1) time daily. Said serving is to be consumed approximately 0 to 60 minutes following a workout or in the morning upon waking on non-workout days.
  • a serving of the dietary supplement comprises the following ingredients in powdered beverage mix form.
  • the dietary supplement comprises for example: about 75 g of pharma grade Dextrose 99 DE, about 9 g of finely grinded Creatine monohydrate, about 2.1 g of Taurine, about 1 g of fine-milled Creatine monohydrate, about 0.33 g of Dipotassium Phosphate, about 0.33 g of Disodium Phosphate, about 0.26 g of the Sodium salt of Alpha Lipoic Acid, about 0.025 g of an extract of Mulberry, about 0.003 g of Chromium polynicotinate, about 0.001 of Anhydrous Creatine, about 0.001 g of Dicreatine malate, about 0.001 g of Creatine HCA salt, about 0.001 g of Taurine ethyl ester HCl, about 0.001 g of Glutamine AKG 2:1, about 0.001 g of Glutamine ethyl ester
  • a dietary supplement As a dietary supplement, 2 scoops, comprising about 100 g total mass of the dietary supplement are administered by a means of mixing said dietary supplement in 360-450 ml of an acceptable aqueous fluid at least one (1) time daily. Said serving is to be consumed approximately 0 to 60 minutes following a workout or in the morning upon waking on non-workout days.
  • a serving of the dietary supplement comprises the following ingredients in powdered beverage mix form.
  • the dietary supplement comprises for example: about 75 g of pharma grade Dextrose 99 DE, about 9 g of finely grinded Creatine monohydrate, about 2.1 g of Taurine, about 1 g of fine-milled Creatine monohydrate, about 0.33 g of Dipotassium Phosphate, about 0.33 g of Disodium Phosphate, about 0.33 g of Magnesium Phosphate, about 0.26 g of Sodium Alpha Lipoic Acid, about 0.1 g of Double Fermented Triticum aestivum , about 0.025 g of an extract of Mulberry, about 0.003 g of Chromium polynicotinate, about 0.001 g of Anhydrous Creatine, about 0.001 g of Creatine Dicreatine malate, about 0.001 g of Creatine pyroglutamate, about 0.001 g of Creatine HCA salt
  • a dietary supplement As a dietary supplement, 2 scoops, comprising about 100 g total mass of the dietary supplement are administered by a means of mixing said dietary supplement in 360-450 ml of an acceptable aqueous fluid at least one (1) time daily. Said serving is to be consumed approximately 0 to 60 minutes following a workout or in the morning upon waking on non-workout days.

Abstract

The present invention relates to the composition of a dietary supplement provided for increasing Creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and aiding in recovery following exercise as well as supporting the immune system during periods of intense training. A method for achieving the same is also provided. The present invention comprises at least Creatine or derivatives thereof, Taurine or derivatives thereof and a source of Phosphate. The dietary supplement may further comprise one or more of the following: Double Fermented Triticum aestivum, Dextrose, Isomalt, Trehalose, D-Mannose, Mulberry extract, Enicostemma littorale Blume, Scoparia dulcis, Tarragon extract, Andrographis paniculata, Chromium or derivatives thereof, Glutamine and Alpha Lipoic Acid.

Description

    RELATED APPLICATIONS
  • This application is a continuation of the applicant's co-pending U.S. application Ser. No. 11/552,266, filed Sep. 14, 2006 which in turn claims priority to U.S. Provisional Patent Application Ser. No. 60/776,325 entitled “Compositions and method for increasing bioavailability of compositions for performance improvement”, file Feb. 23, 2006. The entirety of all of these are incorporated herein by reference.
    • FIELD OF THE INVENTION
  • The present invention relates to the composition of a dietary supplement provided for increasing Creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and aiding in recovery following exercise as well as providing support for the immune system during intense periods of exercise.
  • Furthermore, a method for achieving the same by way of administration of the composition is presented.
    • SUMMARY OF THE INVENTION
  • The foregoing needs, and other needs and objective which will become apparent for the following description, are achieved in the present invention which comprises a dietary composition and method for enhancing Creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing lean muscle mass, and supporting the immune system of an individual, e.g., a human or an animal during intense training periods. According to an embodiment of the present invention, there are provided compositions and methods which minimize catabolism and promote muscle anabolism, particularly in response to exercise. For example the compositions and methods may allow an individual to increase muscle size, strength or endurance training as well as reduce recovery time and facilitate an increased training volume leading to the same.
  • According to an embodiment of the present invention, there are provided compositions and methods which comprise at least a combination of Creatine or derivatives thereof, Taurine or derivatives thereof and a source of Phosphate.
  • According to additional or alternative embodiments of the present invention, there are provided compositions and methods that further comprise at least one of Double Fermented Triticum aestivum, Dextrose, Isomalt, Trehalose, D-Mannose, an extract of Mulberry, Enicostemma littorale Blume, Scoparia dulcis, an extract of Tarragon, Andrographis paniculata, Chromium or derivatives thereof, Glutamine and Alpha Lipoic Acid.
    • DETAILED DESCRIPTION OF THE INVENTION
  • In the following description, for the purposes of explanation, numerous specific details are set forth in order to provide a thorough understanding of the present invention. It will be apparent, however, to one skilled in the art that the present invention may be practiced without these specific details.
  • The present invention, according to various embodiments thereof, is directed to a dietary supplement for increasing Creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and aiding in post-exercise recovery as well as providing support for the immune system during intense exercise training periods. The present invention comprises at least a source of Creatine or derivative thereof, Taurine or derivative thereof and a source of Phosphate. According to various embodiments, the present invention may further comprise combinations of Double Fermented Triticum aestivum, Dextrose, Isomalt, Trehalose, D-Mannose, an extract of Mulberry, Enicostemma littorale Blume, Scoparia dulcis, an extract of Tarragon, Andrographis paniculata, Chromium or derivatives thereof, Glutamine and Alpha Lipoic Acid.
    • Definitions
  • As used herein, the term “derivative” refers to a compound, such as a salt, ester, or amine, which can readily supply a closely related biologically active compound, either upon administration or upon exposure to specific environmental conditions, such as pH, temperature, etc. For example, a “derivative” of creatine can be a salt, ester or amine of creatine, so long as the derivative can readily supply biologically active creatine. For a given compound, the skilled person in the art will readily recognize and envisage those closely related compounds which should be considered “derivatives.”
  • Thus, for example, a derivative of a particular substance may comprise a form of that substance which has been modified through reaction. Other derivatives are forms of a given substance that are precursors of that substance which would give rise to that substance after modification. Reactions involved in the formation of derivatives include, but are not limited to: hydroxylation, esterification, amide formation and salt formation.
  • As used herein, “Carbohydrate” refers to at least a source of carbohydrates such as, but not limited to, monosaccharides, disaccharides, oligosaccharides, polysaccharides or derivatives thereof.
  • As used herein, “Creatine” refers to the chemical N-methyl-N-guanyl Glycine, (CAS Registry No. 57-00-1), also known as, (alpha-methyl guanido) acetic acid, N-(aminoiminomethyl)-N-glycine, Methylglycocyamine, Methylguanidoacetic Acid, or N-Methyl-N-guanylglycine. Additionally, as used herein, “Creatine” also includes derivatives of Creatine such as esters, and amides, and salts, as well as other derivatives, including derivatives that become active upon metabolism. Furthermore, Creatinol (CAS Registry No. 6903-79-3), also known as Creatine-O-Phosphate, N-methyl-N-(beta-hydroxyethyl)guanidine O-Phosphate, Aplodan, or 2-(carbamimidoyl-methyl-amino)ethoxyphosphonic acid, is henceforth in this disclosure considered to be a Creatine derivative.
  • As used herein, “Phosphate” refers to at least a source of Phosphate ions such as, but not limited to, Dipotassium Phosphate, Disodium Phosphate, Magnesium Phosphate or derivatives thereof.
  • Carbohydrate ingestion is known to stimulate the secretion of insulin which in turn facilitates the uptake of glucose into skeletal muscle via glucose transporter 4 (GLUT4) translocation (Wang et al., J Cell Biol. 1996 135:415-30). Glucose is then converted to and stored as glycogen and triglycerides. Concomitant with this, insulin inhibits the release and synthesis of glucose (Khan et al., Diabetologia. 2002 45:1475-83). Moreover, insulin also plays an important role in protein metabolism where it inhibits the breakdown of protein or proteolysis (Volpi E and Wolfe B. In: Handbook of Physiology, L. Jefferson and A. Cherrington (eds.) New York: Oxford, 2001, p. 735-757; Boirie et al., J Clin Endocrinol Metab. 2001 86:638-44). Furthermore, insulin promotes the uptake of amino acids into muscle and stimulates protein synthesis (Biolo et al., J Clin Invest. 1995 95:811-9), particularly following exercise (Biolo et al., Diabetes. 1999 48:949-57). Insulin has also been shown to stimulate Creatine uptake by muscle cells (Odoom et al., Mol Cell Biochem. 1996 158:179-88). Alpha Lipoic Acid has been shown to have insulin-like properties, which further aid in the retention of Creatine. (Streeper et al., Am J. Physiol. 1997 273(1 Pt 1):E185-91; Ziegler et al., Diabetes Care. 1999 22:1296-301). Via the combination of Creatine with Alpha Lipoic Acid and a small amount of carbohydrate, Creatine retention as compared to Creatine and carbohydrate alone is significantly improved (Burke et al., Int J Sport Nutr Exerc Metab. 2003 13:294-302). Therefore, it is deemed to be advantageous, that for the purposes of Creatine retention, the actions of insulin be enhanced. Furthermore, it may be advantageous to increase the activity and availability of Creatine in skeletal muscle.
  • Combinations comprising some of the aforementioned ingredients have been shown to offer further benefit to muscle building and increasing strength. In one clinical trial, 32 males were divided into four groups of eight subjects. Group 1 received a combination of Creatine/Dextrose/Taurine/Alpha Lipoic Acid, Group 2 received Creatine plus grape juice, Group 3 received Creatine plus water, and group 4 a placebo. At Day 28 of the experiment, Group 1 had demonstrated greater improvements in body composition and muscular endurance as compared to the other three groups (Kalman et al., Med Sci Sports Exerc. 2000, 32, Supplement abstract 562). In a further study Creatine/Dextrose/Alpha Lipoic Acid was found to provide improved results versus supplementation with whey protein alone in terms of muscle mass gain (Kalman et al., FASEB. 2000, 14:A619). In an eight week study which included diet and weight training, subjects consuming a combination comprising Creatine/Dextrose/Taurine/Ascorbic Acid/Chromium/Alpha Lipoic Acid/Phosphorus gained significantly more mass than subjects consuming Protein/Dextrose alone (Tamopolsky et al., Med Sci Sports Exerc. 2001 33(:2044-52).
  • Not wishing to be bound by theory, it is herein believed that the activity of insulin initiated by the ingestion of carbohydrates, such as Dextrose as comprised in the present invention, can be enhanced and sustained by insulin potentiators such as, including but not limited to, Taurine, Alpha Lipoic Acid, an extract of Mulberry, Chromium, Glutamine, Enicostemma littorale Blume, Scoparia dulcis, an extract of Tarragon and Andrographis paniculata. In another embodiment, the present invention may comprise one or more of Isomalt, Trehalose or D-Mannose to further potentiate the secretion or activity of insulin. The enhanced activity of insulin may facilitate increased uptake and retention of Creatine, as incorporated into the present invention, by skeletal muscle. Subsequently, the increase in Creatine retention may facilitate increased muscle growth, increased muscle endurance and reduced post-exercise recovery time by virtue of the biological role of Creatine. Furthermore, advantageously, the biological role of Creatine may be aided by ensuring adequate Phosphate availability by the addition of supplemental Phosphates.
    • Creatine
  • Creatine is a naturally occurring amino acid derived from the amino acids glycine, arginine, and methionine. Although it is found in meat and fish, it is also synthesized by humans. Creatine is predominantly used as a fuel source in muscle. About 65% of Creatine is stored in muscle as Phosphocreatine (Creatine bound to a Phosphate molecule) (Casey et al., Am J. Physiol. 1996 271:E38-43). Muscular contractions are fueled by the dephosphorylation of adenosine triphosphate (ATP) to produce adenosine diphosphate (ADP) and without a mechanism to replenish ATP stores, the supply of ATP would be totally consumed in 1-2 seconds (Casey and Greenhaff, Am J Clin Nutr. 2000 72:607 S-17S). Phosphocreatine serves as a major source of Phosphate from which ADP is regenerated to ATP. Six seconds following the commencement of exercise, muscular concentrations of Phosphocreatine drop by almost 50% (Gaitanos et al., J Appl Physiol. 1993 75:712-9).
  • Creatine supplementation has been shown to increase the concentration of Creatine in the muscle (Harris et al., Clin Sci (Lond). 1992 83:367-74) and further said supplementation enables an increase in the resynthesis of Phosphocreatine (Greenhaff et al., Am J. Physiol. 1994 266:E725-30) leading to a rapid replenishment of ATP within the first two minutes following the commencement of exercise.
  • In the early 1990's it was first clinically demonstrated that supplemental Creatine can improve strength and reduce fatigue (Greenhaff et al., Clin Sci (Lond). 1993 84:565-71). Resistance training with supplemented creatine experiments display a result of increased strength and fat-free mass over a placebo in sedentary females (Vandenberghe et al., J Appl Physiol. 1997 83:2055-63) and in male football players (Vandenberghe et al., J Appl Physiol. 1997 83:2055-63). In addition to increasing fat-free mass and strength, Creatine supplementation increases muscle fiber cross sectional area (Volek et al., Med Sci Sports Exerc. 1999 31:1147-56) thereby increasing muscle volume. High-intensity exercise performance of both males and females is also improved by supplemental Creatine (Tarnopolsky et al., Int J Sport Nutr Exerc Metab. 2000 10:452-63; Burke et al., Int J Sport Nutr Exerc Metab. 2000 10:235-44). Creatine supplementation may also benefit individuals with muscle dystrophy disorders by reducing muscle loss (Walter et al., Neurology. 2000 54:1848-50).
  • Furthermore, there is evidence that Creatine may have antioxidant properties (Lawler et al., Biochem Biophys Res Commun. 2002 290:47-52; Sestili et al., Free Radic Biol Med. 2006 40:837-49). The antioxidant activity of Creatine may additionally aid post-exercise muscle recovery.
  • Creatine retention has been shown to be markedly improved by the concomitant ingestion with carbohydrates, up to 60% better, which may further be related to increased insulin concentration (Green et al., Am J. Physiol. 1996 271:E821-6). Furthermore, glucose and Creatine uptake by muscle cells has been shown to be stimulated by insulin (Odoom et al., Mol Cell Biochem. 1996 158:179-88). Thus, the ingestion of Creatine combined with a source of carbohydrates is recommended to improve retention. It may also be beneficial to include a source of protein at the time of Creatine ingestion (Steenge et al., J Appl Physiol. 2000 89:1165-71).
  • U.S. Pat. No. 5,767,159 purports to describe a method for increasing muscle capacity and replenishing ATP by administering daily Creatine in healthy mammals. The amount of said Creatine is at least 0.2-0.4 g per kg body weight and not less than 15 g in a 70 kg mammal to be taken for at least 2 days but not more than 7 days. The Creatine is administered in solution which may further include other conventional nutrients such as lipids, carbohydrates, amino acids, electrolytes, trace elements and vitamins.
  • U.S. Pat. No. 5,968,544 purports to describe compositions containing Creatine for human consumption suitable for use in a drink or as dry powder stable for storage. The Creatine is provided in an acidic yogurt-based semi-liquid composition or forms an acidic solution when mixed with water.
  • U.S. Pat. No. 5,973,199 purports to describe compositions for water soluble Creatine salts usable in foods.
  • U.S. Pat. No. 5,968,900 purports to describe compositions and methods for increasing Creatine and glycogen concentration in muscle by increasing blood plasma insulin concentration. In one described embodiment, the compositions described are composed of Creatine or Creatine derivatives with a carbohydrate, wherein the carbohydrate is said to cause an increase in blood plasma insulin levels, which results in increases in Creatine retention.
  • In an embodiment of the present invention, which is set forth in greater detail in the examples below, the dietary supplement includes Creatine or derivatives thereof. A serving of the dietary supplement may include from about 3 g to about 15 g of Creatine or derivatives thereof. The preferred dosage of a serving of the dietary supplement comprises about 10 g of Creatine or derivatives thereof.
    • Taurine
  • Taurine, an amino acid found primarily in nerve and muscle tissue, is generally considered to be a conditionally-essential amino acid, being only required under certain circumstances. As it is not utilized for protein synthesis, Taurine is found in the free form or in some small peptides. The accumulation of Taurine within cells is mediated via a high affinity sodium-dependent transporter (Ramamoorthy et al., Biochem J. 1994 300:893-900). The expression of this Taurine transporter is induced by differentiation program of myocytes (muscle cells) (Uozumi et al., Biochem J. 2006 394:699-706). Exercise-induced hormones also known to activate the Taurine transporter (Park et al., Biofactors. 2004 21:403-6). Moreover, genetically modified mice lacking the Taurine transporter have depleted Taurine levels in all muscle and have impaired skeletal muscle function (Warskulat et al., FASEB J. 2004 18:577-9)
  • One of the main roles of Taurine is the regulation of fluid balance and is released by contracting muscles (Cuisinier et al., Eur J Appl Physiol. 2002 87:489-95). Taurine has also been shown to modulate the contractile function of mammalian skeletal muscle (Bakker et al., J. Physiol. 2002 538:185-94). In rats, the Taurine concentration in muscle decreases as a result of exercise (Matsuzaki et al., Med Sci Sports Exerc. 2002 34:793-7) and oral supplementation with Taurine has been shown to maintain the concentration of Taurine in muscle and prolong exercise performance (Miyazaki et al., Amino Acids. 2004 27:291-8; Yatabe et al., J Orthop Sci. 2003; 8:415-9).
  • In a model of spontaneous diabetes, Taurine supplementation has been shown to improve insulin sensitivity in rats (Nakaya et al., Am J Clin Nutr. 2000 71:54-8). Furthermore, Taurine improves glucose metabolism in insulin resistant rats (Nandhini et al., Amino Acids. 2002; 22:27-38), suggesting that Taurine has insulin-like properties which may improve Creatine uptake and retention within muscle cells. Supplementation with Taurine has additionally been shown to reduce exercise-induced oxidative damage and enhance recovery (Zhang et al., Amino Acids. 2004 26:203-7).
  • In an embodiment of the present invention, which is set forth in greater detail in the examples below, the dietary supplement includes Taurine or derivatives thereof. A serving of the dietary supplement may include from about 0.5 g to about 3 g of Taurine or derivatives thereof. The preferred dosage of a serving of the dietary supplement comprises about 2.1 g of Taurine or derivatives thereof.
    • Phosphate
  • Phosphate, or phosphorus, is the second most abundant mineral in the body with calcium being the most abundant. As a Phosphate salt with calcium, Phosphate is involved in the formation of bone and teeth. In other salt complexes, Phosphate is involved in acid-base balance. Phosphate is also important for the structures of DNA and cell membranes. One of the most important roles of Phosphate is energy production in muscle as ATP and Phosphocreatine. Phosphate is also part of a compound in red blood cells known as 2,3 DPG (2,3-diphosphoglycerate), which facilitates the release of oxygen to the muscle tissues.
  • Supplemental Phosphate salts have been shown to increase the concentration of 2,3 DPG in red blood cells, increasing VO2 max (a measure of aerobic fitness) and a reduction in the production of lactate (Cade et al., Med Sci Sports Exerc. 1984 16:263-8). Moreover, Phosphate has also been shown to enhance oxygen uptake and run performance without affecting the level of 2,3 DPG (Kreider et al., Med Sci Sports Exerc. 1990 22:250-6).
  • The metabolic rate can also be increased by Phosphate supplementation (Nazar et al., J Physiol Pharmacol. 1996 47:373-83).
  • In an embodiment of the present invention, which is set forth in greater detail in the examples below, the dietary supplement includes a source of Phosphate or derivatives thereof. A serving of the dietary supplement may include from about 0.1 g to about 1.5 g of Phosphate or derivatives thereof. The preferred dosage of a serving of the dietary supplement comprises about 0.18 g of elemental Phosphate or derivatives thereof.
    • Alpha Lipoic Acid
  • Alpha Lipoic Acid (ALA) is an enzyme found in the cellular energy-producing structures, the mitochondria. ALA works in synergy with vitamins C and E as an antioxidant in both the water- and fat-soluble environments.
  • In rats supplemented with ALA the negative age-related changes in mitochondrial function, accumulated oxidative damage and metabolic rate were all improved (Hagen et al., FASEB J. 1999 13:411-8). As such, the antioxidant activity of ALA is likely involved in the prevention of cell death due to an improvement in oxidative stress (Arivazhagan et al., Pharmacol Res. 2000 41:299-303). Furthermore, ALA has been linked to a beneficial increase in high-density lipoproteins (Wollin et al., J Nutr Biochem. 2004 15:402-10) possibly due to its known effects as an antioxidant.
  • Additionally, ALA appears to possess a dual action related to hunger and >oxidation of fat. First, the activity of AMP-activated protein kinase, which acts as an energy sensor in the hypothalamus, is reduced by ALA in rodents, this results in a profound weight loss by reducing food intake and enhancing energy expenditure (Kim et al., Nat Med. 2004 10:727-33). Second, ALA increases Uncoupling Protein-1 in rodent adipocytes while increasing AMP-activated protein kinase in skeletal muscle cells and increasing glucose uptake and energy expenditure (Lee et al., Int J Biochem Cell Biol. 2005 37:2254-9). Therefore, ALA seemingly has different effects in different tissues.
  • However, in adipocytes or muscle cells ALA increases fatty acid oxidation, leading to an increase in energy expenditure and a decrease in weight and food intake.
  • U.S. Pat. Nos. 6,136,339 and 6,620,425 disclose compositions and methods for enhancing an athlete's muscle size or strength using a combination of Creatine, Alpha Lipoic Acid and optionally Dextrose, to be taken mixed with water daily following exercise.
  • In an embodiment of the present invention, which is set forth in greater detail in the examples below, the dietary supplement may include Alpha Lipoic Acid or derivatives thereof. A serving of the dietary supplement may include from about 0.005 g to about 0.4 g of Alpha Lipoic Acid or derivatives thereof. The preferred dosage of a serving of the dietary supplement comprises about 0.25 g of Alpha Lipoic Acid or derivatives thereof.
    • Dextrose
  • Dextrose is a simple sugar or monosaccharide commonly known as D-glucose. Also known as ‘grape sugar’ or ‘blood sugar’, it is found mainly in honey and fruits and is a building-block of glycogen, cellulose and starch. Recently, Dextrose was shown to boost the performance a female rowers as compared to ribose, which had been theorized to replenish muscle energy (Dunne et al., Clin J Sport Med. 2006 16:68-71).
  • In an embodiment of the present invention, which is set forth in greater detail in the examples below, the dietary supplement may include Dextrose. A serving of the dietary supplement may include from about 50 g to about 100 g of Dextrose. The preferred dosage of a serving of the dietary supplement comprises about 75 g of Dextrose.
    • Mulberry Extract
  • Mulberry (Morus alba) is an edible plant used in Chinese medicine which is rich in flavonoids possessing antioxidant activity (Doi et al. Chem Pharm Bull (Tokyo). 2001 49:151-3). Orally administered mulberry extracts of Mulberry reduced blood glucose levels of both non-diabetic and streptozotocin-treated diabetic rats, commensurate with decreased food intake (Musabayane et al., Methods Find Exp Clin Pharmacol. 2006 28:223-8). Orally consumed extracts of Mulberry have also been shown to inhibit increases in blood glucose resulting from the ingestion of carbohydrates such as sucrose in humans and rats (Oku et al., Br J. Nutr. 2006 95:933-8). Furthermore, extracts of Mulberry confer neuroprotective benefits (Kang et al., Biol Pharm Bull. 2006 29:270-4) and may further attenuate the development of atherosclerotic lesions (Enkhmaa et al., J. Nutr. 2005 135:729-34).
  • In an embodiment of the present invention, which is set forth in greater detail in the examples below, the dietary supplement may include Mulberry extract. A serving of the dietary supplement may include from about 0.01 g to about 0.05 g of Mulberry extract. The preferred dosage of a serving of the dietary supplement comprises about 0.025 g of Mulberry extract.
    • Chromium
  • Chromium is an essential trace mineral that is used to control blood sugar levels by aiding insulin, which can help control or reduce weight. Chromium is poorly absorbed by the body and must therefore be combined with a more efficiently absorbed compound such as niacin as in the case of polynicotinate. Chromium likely exerts its main function as a component or a co-factor of the glucose tolerance factor, which is involved in insulin sensitivity.
  • Chromium has been shown clinically to increase lean mass (Bahadori et al., Acta Med Austriaca. 1997 24:185-7) and reduce body fat when combined with exercise (Grant et al., Med Sci Sports Exerc. 1997 29:992-8). Moreover, chromium has also been shown to increase high density lipoproteins (HDL i.e. ‘good’ cholesterol) (Riales et al., Am J Clin Nutr 1981; 34:2670-8). Numerous clinical studies have demonstrated the relationship between supplemental Chromium and improved insulin activity and glucose metabolism (Anderson, Diabetes Metab. 2000 26:22-7).
  • In an embodiment of the present invention, which is set forth in greater detail in the examples below, the dietary supplement may include a derivative of Chromium. A serving of the dietary supplement may include from about 0.001 g to about 0.005 g of a derivative of Chromium. The preferred dosage of a serving of the dietary supplement comprises about 0.003 g of a derivative of Chromium.
    • Glutamine
  • Glutamine is the most abundant amino acid found in muscle and has important functions as a precursor for the synthesis of other amino acids. Many cells required for immune function rely on Glutamine as source for energy production.
  • Physical activity can deplete Glutamine levels, and as such, Glutamine is often considered to be a ‘conditionally essential’ amino acid. A study examining the Glutarine levels of groups involved in several different types of activities or sports found that powerlifters and swimmers had lower Glutamine levels than cyclists and non-athletes (Hiscock and Mackinnon, Med Sci Sports Exerc. 1998 30:1693-6), suggesting that high resistance load activities require increased amounts of Glutamine. Moreover, this depletion of Glutamine has been linked to immunosuppression often resulting from intense training (Newsholme, Int J Sports Med. 1994 15:S142-7). Supplementation with Glutamine in conjunction with additional antioxidants can increase body weight, body cell mass and intracellular water when compared with placebo (Shabert et al., Nutrition. 1999 15:860-4). Glutamine is also capable of stimulating insulin secretion (Tanizawa et al., Diabetes. 2002 51:712-7).
  • In an embodiment of the present invention, which is set forth in greater detail in the examples below, the dietary supplement may include Glutamine or a derivative thereof. A serving of the dietary supplement may include from about 0.001 g to about 0.005 g of Glutamine or a derivative thereof. The preferred dosage of a serving of the dietary supplement comprises about 0.002 g of Glutamine or a derivative thereof.
  • Enicostemma littorale Blume
  • Enicostemma littorale Blume is a flower-producing herb found in South America, Africa, and Asia. In rat models of diabetes, Enicostemma littorale extract can enhance glucose-induced insulin release thereby effectively lowering blood glucose levels (Maroo et al., J. Ethnopharmacol. 2002 81:317-20; Maroo et al., Phytomedicine. 2003 10:196-9).
  • Furthermore, Enicostemma littorale extract counters the changes in several metabolic enzymes and antioxidants observed in diabetic rats, including lowering thiobarbituric acid reactive substances and lipid hydroperoxides while increasing the concentration of reduced glutathione and the activities of superoxide dismutase and catalase (Srinivasan et al., J Pharm Pharmacol. 2005 57:497-503). The lipid profile of rats fed cholesterol was also improved by administration of Enicostemma littorale extract (Vasu et al., J. Ethnopharmacol. 2005 101:277-82).
  • In an embodiment of the present invention, which is set forth in greater detail in the examples below, the dietary supplement may include Enicostemma littorale Blume. A serving of the dietary supplement may include from about 0.0005 g to about 0.003 g of Enicostemma littorale Blume. The preferred dosage of a serving of the dietary supplement comprises about 0.001 g of Enicostemma littorale Blume.
  • Scoparia dulcis (Scotch brum)
  • Scoparia dulcis is a tropical herb found in abundance in South America and the Amazon rainforest and has been used traditionally for multiple treatments including diabetes. Extracts of Scoparia dulcis provide both antidiabetic and antihyperlipidemic actions in normal and experimentally diabetic rats (Pari and Latha, J Med Food. 2006 9:102-7). Scoparia dulcis extract has also demonstrated antioxidant and neuroprotective activity (Pari and Latha, BMC Complement Altem Med. 2004 4:16).
  • In an embodiment of the present invention, which is set forth in greater detail in the examples below, the dietary supplement may include Scoparia dulcis. A serving of the dietary supplement may include from about 0.0005 g to about 0.003 g of Scoparia dulcis. The preferred dosage of a serving of the dietary supplement comprises about 0.001 g of Scoparia dulcis.
  • Tarragon extract (Artemisia dracunculus)
  • Russian Tarragon (Artemisia dracunculus) is a perennial herb widely used in cooking. Historically, it has been used as a natural blood cleanser and as a treatment for headaches and dizziness. Current studies are examining the use of an ethanolic extract of Russian Tarragon for the treatment of hyperglycemia associated with diabetes. The toxicology of this extract has been evaluated, and has been shown to be safe and non-toxic (Ribnicky et al., Food Chem Toxicol. 2004 42:585-98). Essential oil extracted from Artemisia dracunculus may also have potential as an anticonvulsant and as a mild sedative (Sayyah et al., J. Ethnopharmacol. 2004 94:283-7).
  • In an embodiment of the present invention, which is set forth in greater detail in the examples below, the dietary supplement may include Tarragon extract. A serving of the dietary supplement may include from about 0.0005 g to about 0.003 g of Tarragon extract. The preferred dosage of a serving of the dietary supplement comprises about 0.001 g of Tarragon extract.
  • Andrographis paniculata
  • Andrographis paniculata is a medicinal herb used traditionally throughout Asia to treat a number of conditions. Clinical studies have demonstrated an immunity-enhancing benefit of Andrographis paniculata supplementation by reducing the occurrence and severity of common cold symptoms (Caceres et al., Phytomedicine. 1999 6:217-23) and upper-respiratory tract infections (Melchior et al., Phytomedicine. 2000 7:341-50).
  • Additionally, Andrographis paniculata has been shown to possess antipyretic, fever-reducing, activity similar to that of aspirin (Vedavathy and Rao, J. Ethnopharmacol. 1991 33:193-6). Furthermore, Andrographis paniculata has been shown to reduce chemically-induced liver toxicity in experimental mice (Kapil et al., Biochem Pharmacol. 1993 46:182-5).
  • Andrographis paniculata extract possesses antihyperglycaemic and antioxidative activities in both normal and chemically-induced diabetic rats (Zhang and Tan, Clin Exp Pharmacol Physiol. 2000 27:358-63). The antidiabetic properties of Andrographis paniculata are believed to be due at least in part to enhanced glucose metabolism (Zhang and Tan, Acta Pharmacol Sin. 2000 21:1157-64).
  • In an embodiment of the present invention, which is set forth in greater detail in the examples below, the dietary supplement may include Andrographis paniculata. A serving of the dietary supplement may include from about 0.0005 g to about 0.003 g of Andrographis paniculata. The preferred dosage of a serving of the dietary supplement comprises about 0.001 g of Andrographis paniculata.
  • Double Fermented Triticum aestivum
  • Double Fermented Triticum aestivum is a whole-grain wheat product low in simple sugars and high in complex carbohydrates. This produces a more level glucose/insulin response rather than the typical “spike” resulting from simple sugar ingestion. As such, Double Fermented Triticum aestivum is marketed towards overweight or obese individuals or individuals with impaired glucose tolerance. Double Fermented Triticum aestivum was found effective at reducing the risks associated with development of type 2 diabetes such as elevated fasting blood glucose levels and obesity (Rave et al., 65th Annual Scientific Sessions, American Diabetes Association 2005, Abstract 1765-P).
  • In an embodiment of the present invention, which is set forth in greater detail in the examples below, the dietary supplement may include Double Fermented Triticum aestivum. A serving of the dietary supplement may include from about 0.05 g to about 0.3 g of Double Fermented Triticum aestivum. The preferred dosage of a serving of the dietary supplement comprises about 0.1 g of Double Fermented Triticum aestivum.
    • Isomalt
  • Isomalt is a disaccharide sugar substitute derived from sucrose which is less sweet than, and is often mixed with, more conventional sweeteners. Being only partially digested in the intestines, isomalt results in a low blood glucose effect, has benefits similar to that of dietary fiber, and has a caloric value of about half that of sugar. Moreover, Isomalt has been shown to promote healthy bowel function without impairing metabolic function (Gostner et al., Br J. Nutr. 2005 94:575-81; Gostner et al. Br J. Nutr. 2006 95:40-50).
  • In an embodiment of the present invention, which is set forth in greater detail in the examples below, the dietary supplement may include Isomalt. A serving of the dietary supplement may include from about 0.0005 g to about 0.003 g of Isomalt. The preferred dosage of a serving of the dietary supplement comprises about 0.001 g of Isomalt.
    • Trehalose
  • Trehalose is a naturally occurring disaccharide found in plants, invertebrates and fungi and is about half as sweet as sucrose or table sugar. Trehalose has been discovered to be able to inhibit the aggregation of some proteins and thus has potential in the prevention of diseases linked to such events such as Huntington's disease (Tanaka et al., Nat Med. 2004 10:148-54).
  • In an embodiment of the present invention, which is set forth in greater detail in the examples below, the dietary supplement may include Trehalose. A serving of the dietary supplement may include from about 0.0005 g to about 0.003 g of Trehalose. The preferred dosage of a serving of the dietary supplement comprises about 0.001 g of Trehalose.
    • D-Mannose
  • Mannose is a monosaccharide found in some fruits including cranberry. It is absorbed slowly in the gastrointestinal tract, with most being excreted in the urine. D-mannose has been theorized to aid in the treatment of urinary tract infections by virtue of being able to bind to the surface proteins of infection-causing bacteria, thereby facilitating their clearance (Schaeffer et al., J. Urol. 1984 131:906-10).
  • In an embodiment of the present invention, which is set forth in greater detail in the examples below, the dietary supplement may include D-mannose. A serving of the dietary supplement may include from about 0.0005 g to about 0.003 g of D-mannose. The preferred dosage of a serving of the dietary supplement comprises about 0.001 g of D-mannose.
  • According to various embodiments of the present invention, the dietary supplement may be consumed in any form. For instance, the dosage form of the dietary supplement may be provided as, e.g., a powder beverage mix, a liquid beverage, a ready-to-eat bar or drink product, a capsule, a liquid capsule, a tablet, a caplet, or as a dietary gel. The preferred dosage form of the present invention is as a powder beverage mix or a drink product.
    • Fine-Milling of Active Constituents
  • As set forth above, the dosage form of the dietary supplement, in accordance with the example embodiments set forth below, may be provided in accordance with customary processing techniques for herbal and/or dietary supplements, wherein the active ingredients are suitably processed into a desired form. In accordance with various embodiments of the present invention, one or more ingredients of the diet supplement are processed so as to form fine-milled particles. For instance, in various embodiments, one or more ingredients of the dietary supplemental are processed by a large-scale dry milling technique that produces fine particles, preferably known as fine-milled particles. The use of dry milling techniques, in combination with excipients and polymers, to form fine-milled particles has been shown to improve flow and dispersability, stability, resistance to moisture, bioavailability, and dissolution/release properties. Formulations benefit by containing fine-milled particles for the purpose of providing the one or more ingredients in particle sizes that optimize one or more of the flow and dispersability, stability, resistance to moisture, bioavailability, and dissolution/release properties of the one or more ingredients in a dietary supplement. In vitro tests designed to simulate the environment of stomach were preformed to test the dissolution rate of fine-milled particle tablets versus non-fine-milled. These test showed that in tablets produced from fine-milled particles the time to 100% dissolution was approximately 15 minutes. In the case of non-fine-milled particle compositions, only 90% dissolution was observed after 120 minutes. In preferred embodiments, the dietary supplemental contains fine-milled particles having and average size between about 50 nm and about 2 nm.
  • U.S. Provisional Patent Application 60/776,325 discloses a method for improving the absorption, palatability, taste, texture, and bioavailability of compounds by increasing the solubility of said compounds in proprietary formulations for the purposes of enhancing or improving muscle size, growth and/or recovery time and/or weight loss. The increased bioavailability of the compound or ingredients is achieved by reducing the particle size via “fine-milling” thereby increasing the surface area-to-volume ratio each particle, thus increasing the rate of dissolution. The compositions and methods disclosed promote increased bioavailability by increasing the total surface area of poorly soluble particles, thereby increasing the rate of absorption.
  • As used herein the, term “fine-milled” and/or “fine-milling” refers to the process of micronization. Micronization is a mechanical process that involves the application of force to a particle, thereby resulting in a reduction in the size of the particle. The force, in the case of micronization may be applied in any manner such as, e.g., the collision of particles at high rates of speed, grinding, or by an air-jet micronizer. In preferred embodiments, fine-milled particles are obtained by jet-milling with nitrogen and compressed air.
  • As used herein, term “particle size” refers to the diameter of the particle. The term “average particle size” means that at least 50% of the particles in a sample will have the specified particle size. Preferably, at least 80% of the particles in a sample will have the specified particle size, and more preferably, at least 90% of the particles in a given sample will have the specified particle size.
  • The size of a particle can be determined any of the methods known within the art. Methods for particle size determination which may be employed are for example, e.g., sieves, sedimentation, electrozone sensing (Coulter counter), microscopy, and/or Low Angle Laser Light Scattering. The preferred methods for the particle size determination of the present invention are those methods which are most commonly used in the pharmaceutical industry, such as laser diffraction, e.g., via light scattering Coulter Delsa 440SX.
  • The fine-milling process may be employed in the processing of one or more of the ingredients of the present invention in the dosage forms of tablets, e.g., immediate-release film coated, modified-release and fast-dissolving; capsules or tablets, e.g., immediate-release and modified-release; liquid dispersions; powders; drink mixes, etc.
  • Preferably, the dietary supplement of the present invention is consumed by an individual in accordance with the following method: As a dietary supplement, a serving of said dietary supplement may be taken by means of mixing in about 360-450 ml of an acceptable aqueous fluid at least one (1) time daily wherein each serving is comprised of two (2) scoops comprising about 100 g total mass of the dietary supplement. Said dietary supplement may be consumed approximately 0 to 60 minutes following a workout, or in the morning upon waking on non-workout days. In this manner, the dietary supplement may increase Creatine uptake and retention in skeletal muscle, increase muscle mass and strength, increase exercise capacity and aid in post-exercise recovery as well as provide support for the immune system during intense exercise training periods
  • Furthermore, the dosage form of the supplemental composition may be provided in accordance with customary processing techniques for herbal and dietary supplements in any of the forms mentioned above. Additionally, the dietary supplement set forth in the example embodiments herein may contain any appropriate number and type of excipients, as is well-known in the art.
  • The present dietary supplement or those similarly envisioned by one of skill in the art, may be utilized in compositions and methods for increasing Creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and aiding in post-exercise recovery as well as providing support for the immune system during intense exercise training periods of an individual, e.g. a human or an animal in a formulation designed to be consumed at least one time per day.
  • Although the following examples illustrate the practice of the present invention in three of its various embodiments, the examples should not be construed as limiting the scope of the invention. Other embodiments will be apparent to one skilled in the art from consideration of the specification and example.
    • EXAMPLE 1
  • A serving of the dietary supplement comprises the following ingredients in powdered beverage mix form. The dietary supplement comprises for example: about 74 g of pharma grade Dextrose 99 DE, about 9 g of Creatine monohydrate, finely grinded, about 2.1 g of Taurine, about 0.33 g of Dipotassium Phosphate, about 0.33 g of Magnesium Phosphate, about 0.26 g of Sodium Alpha Lipoic Acid, about 0.025 g of and extract of Mulberry, about 0.003 g of Chromium polynicotinate, about 0.001 g of Anhydrous Creatine, about 0.001 g of Taurine ethyl ester HCl, about 0.001 g of Glutamine AKG 2:1, about 0.001 g of Glutamine ethyl ester HCl, about 0.001 g of Enicostemma littorale Blume, about 0.001 g of Scoparia dulcis, about 0.001 g of an extract of Tarragon, about 0.001 g of Andrographis paniculata.
  • Directions: As a dietary supplement, 2 scoops, comprising about 100 g total mass of the dietary supplement are administered by a means of mixing said dietary supplement in 360-450 ml of an acceptable aqueous fluid at least one (1) time daily. Said serving is to be consumed approximately 0 to 60 minutes following a workout or in the morning upon waking on non-workout days.
    • EXAMPLE 2
  • A serving of the dietary supplement comprises the following ingredients in powdered beverage mix form. The dietary supplement comprises for example: about 75 g of pharma grade Dextrose 99 DE, about 9 g of finely grinded Creatine monohydrate, about 2.1 g of Taurine, about 1 g of fine-milled Creatine monohydrate, about 0.33 g of Dipotassium Phosphate, about 0.33 g of Disodium Phosphate, about 0.26 g of the Sodium salt of Alpha Lipoic Acid, about 0.025 g of an extract of Mulberry, about 0.003 g of Chromium polynicotinate, about 0.001 of Anhydrous Creatine, about 0.001 g of Dicreatine malate, about 0.001 g of Creatine HCA salt, about 0.001 g of Taurine ethyl ester HCl, about 0.001 g of Glutamine AKG 2:1, about 0.001 g of Glutamine ethyl ester HCl, about 0.001 g of Enicostemma littorale Blume, about 0.001 g of Scoparia dulcis, about 0.001 g of an extract of Tarragon extract, and about 0.001 g of Andrographis paniculata.
  • Directions: As a dietary supplement, 2 scoops, comprising about 100 g total mass of the dietary supplement are administered by a means of mixing said dietary supplement in 360-450 ml of an acceptable aqueous fluid at least one (1) time daily. Said serving is to be consumed approximately 0 to 60 minutes following a workout or in the morning upon waking on non-workout days.
    • EXAMPLE 3
  • A serving of the dietary supplement comprises the following ingredients in powdered beverage mix form. The dietary supplement comprises for example: about 75 g of pharma grade Dextrose 99 DE, about 9 g of finely grinded Creatine monohydrate, about 2.1 g of Taurine, about 1 g of fine-milled Creatine monohydrate, about 0.33 g of Dipotassium Phosphate, about 0.33 g of Disodium Phosphate, about 0.33 g of Magnesium Phosphate, about 0.26 g of Sodium Alpha Lipoic Acid, about 0.1 g of Double Fermented Triticum aestivum, about 0.025 g of an extract of Mulberry, about 0.003 g of Chromium polynicotinate, about 0.001 g of Anhydrous Creatine, about 0.001 g of Creatine Dicreatine malate, about 0.001 g of Creatine pyroglutamate, about 0.001 g of Creatine HCA salt, about 0.001 g of Taurine ethyl ester HCl, about 0.001 g of Glutamine AKG 2:1, about 0.001 g of Glutamine ethyl ester HCl, about 0.001 g of Enicostemma littorale Blume, about 0.001 g of Scoparia dulcis, about 0.001 g of and extract of Tarragon, about 0.001 g of Andrographis paniculata, about 0.001 g of Isomalt, about 0.001 g of Trehalose, about 0.001 g of D-mannose.
  • Directions: As a dietary supplement, 2 scoops, comprising about 100 g total mass of the dietary supplement are administered by a means of mixing said dietary supplement in 360-450 ml of an acceptable aqueous fluid at least one (1) time daily. Said serving is to be consumed approximately 0 to 60 minutes following a workout or in the morning upon waking on non-workout days.
  • Extensions and Alternatives
  • In the foregoing specification, the invention has been described with specific embodiments thereof, however, it will be evident that various modifications and changes may be made thereto without departing from the broader spirit and scope of the invention.
  • All publications which are cited herein are hereby specifically incorporated by reference into the disclosure for the teachings for which they are cited.

Claims (6)

1. A composition comprising:
Creatinol-O-phosphate;
at least one substance selected from the group consisting of Taurine or derivatives thereof, glutamine or derivatives thereof, an extract of Mulberry, Chromium, Enicostemma littorle Blume, Scoparia dulcis, an extract of Tarragon, Andrographis paniculata, Chromium, and Alpha Lipoic Acid;
at least one source of phosphate selected from the group consisting of Dipotassium Phosphate, Disodium Phosphate and Magnesium Phosphate; and
a source of carbohydrates.
2. The composition of claim 1, wherein the source of carbohydrates comprises at least one of monosaccharides, disaccharides, oligosaccharides, polysaccharides or derivatives thereof.
3. The composition of claim 1 further comprising creatine or derivative thereof.
4. A composition comprising:
Creatinol-O-phosphate;
Glutamine AKG;
Dipotassium Phosphate;
Disodium Phosphate; and
a polysaccharide.
5. A composition comprising:
Creatinol-O-phosphate;
Taurine;
Dipotassium Phosphate;
Disodium Phosphate; and
a polysaccharide.
6. The composition of claim 4, further comprising Dicreatine malate.
US12/291,482 2006-02-23 2008-11-10 Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise Abandoned US20090142410A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/291,482 US20090142410A1 (en) 2006-02-23 2008-11-10 Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77632506P 2006-02-23 2006-02-23
US11/522,266 US7749547B2 (en) 2006-02-23 2006-09-14 Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise
US12/291,482 US20090142410A1 (en) 2006-02-23 2008-11-10 Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/552,266 Continuation US20080105946A1 (en) 2006-10-24 2006-10-24 Solid state field emission charge storage

Publications (1)

Publication Number Publication Date
US20090142410A1 true US20090142410A1 (en) 2009-06-04

Family

ID=38433828

Family Applications (8)

Application Number Title Priority Date Filing Date
US11/486,866 Active US7476405B2 (en) 2006-02-23 2006-07-14 Compositions and methods for the induction and maintenance of quality sleep
US11/505,779 Expired - Fee Related US7794749B2 (en) 2006-02-23 2006-08-16 Rapidly dissolving solid oral dosage form for delivery of composition for increasing nitric oxide activity
US11/522,266 Expired - Fee Related US7749547B2 (en) 2006-02-23 2006-09-14 Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise
US11/709,525 Abandoned US20070202165A1 (en) 2006-02-23 2007-02-21 Method for a supplemental dietary composition having a multi-phase dissolution profile
US11/709,526 Abandoned US20070202166A1 (en) 2006-02-23 2007-02-21 Method for increasing the rate and consistency of bioavailability of supplemental dietary ingredients
US11/821,229 Expired - Fee Related US7906154B2 (en) 2006-02-23 2007-06-21 Compositions and methods for the induction and maintenance of quality sleep
US12/206,892 Expired - Fee Related US7914826B2 (en) 2006-02-23 2008-09-09 Method for promoting sleep
US12/291,482 Abandoned US20090142410A1 (en) 2006-02-23 2008-11-10 Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise

Family Applications Before (7)

Application Number Title Priority Date Filing Date
US11/486,866 Active US7476405B2 (en) 2006-02-23 2006-07-14 Compositions and methods for the induction and maintenance of quality sleep
US11/505,779 Expired - Fee Related US7794749B2 (en) 2006-02-23 2006-08-16 Rapidly dissolving solid oral dosage form for delivery of composition for increasing nitric oxide activity
US11/522,266 Expired - Fee Related US7749547B2 (en) 2006-02-23 2006-09-14 Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise
US11/709,525 Abandoned US20070202165A1 (en) 2006-02-23 2007-02-21 Method for a supplemental dietary composition having a multi-phase dissolution profile
US11/709,526 Abandoned US20070202166A1 (en) 2006-02-23 2007-02-21 Method for increasing the rate and consistency of bioavailability of supplemental dietary ingredients
US11/821,229 Expired - Fee Related US7906154B2 (en) 2006-02-23 2007-06-21 Compositions and methods for the induction and maintenance of quality sleep
US12/206,892 Expired - Fee Related US7914826B2 (en) 2006-02-23 2008-09-09 Method for promoting sleep

Country Status (7)

Country Link
US (8) US7476405B2 (en)
EP (2) EP1991241A4 (en)
JP (1) JP2009527504A (en)
AU (2) AU2006338839A1 (en)
CA (3) CA2642761A1 (en)
WO (5) WO2007095716A1 (en)
ZA (1) ZA200807489B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015050809A1 (en) * 2013-10-01 2015-04-09 Novozymes A/S Processes of producing fermentation products
US10869843B2 (en) 2010-11-23 2020-12-22 Chemi Nutra Method for increasing muscle mass and strength

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5214464B2 (en) 2005-12-28 2013-06-19 アドバンスド バイオニュートリション コーポレーション Delivery medium for probiotic bacteria, in the form of glass, comprising a dry matrix of polysaccharides, saccharides and polyols and method for producing the same
US20080254121A1 (en) * 2007-04-10 2008-10-16 Iomedix Sleep International Srl Multi-layer melatonin composition
JP5714227B2 (en) * 2007-05-31 2015-05-07 サントリーホールディングス株式会社 Anti-fatigue agent and oral composition containing andrographolide as active ingredient
WO2009047004A1 (en) * 2007-10-10 2009-04-16 Daniel Farrington A homeopathic complex
US20090156634A1 (en) * 2007-12-12 2009-06-18 Iovate T. & P. Inc. Tropane alkaloids and trigonelline combinations and methods for administering the same
US20090203789A1 (en) * 2008-01-31 2009-08-13 Multi Formulations Ltd. Fast Dissolution Amino Acid Composition
US20090304602A1 (en) * 2008-06-06 2009-12-10 Tuchinsky David B Nutritional supplement
WO2009147229A1 (en) * 2008-06-06 2009-12-10 Phytolab Gmbh & Co. Kg Synergistic enhancement of cellular ergogenic nutrient uptake, like creatine or carnitine, with tarragon
CA2732892C (en) * 2008-08-15 2020-12-15 Forest Laboratories Holdings Limited Stable solid formulation of a gc-c receptor agonist polypeptide suitable for oral administration
US20100124587A1 (en) * 2008-11-17 2010-05-20 Heuer Marvin A Creatine-containing vitamin and mineral composition
JP5558016B2 (en) * 2009-03-17 2014-07-23 株式会社 資生堂 Circadian rhythm regulator
US20100256215A1 (en) * 2009-04-02 2010-10-07 Silver Eagle Labs Nv, Llc Menthol-Melatonin Dissolving Film
US20100256197A1 (en) * 2009-04-02 2010-10-07 Silver Eagle Labs Nv, Llc Nicotine Dissolving Film With Or Without Menthol
CN102459568A (en) 2009-05-26 2012-05-16 先进生物营养公司 Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
US8748573B2 (en) * 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
US9445622B2 (en) * 2009-12-21 2016-09-20 Glanbia Nutritionals (Ireland) Ltd. Compositions and methods for improving creatine solubility and stability
EP2533791B1 (en) * 2009-12-21 2017-01-25 Glanbia Nutritionals (Ireland) Ltd. Leucine/peptide composition and method of formulation
PL2529004T3 (en) 2010-01-28 2017-12-29 Advanced Bionutrition Corporation Dry glassy composition comprising a bioactive material
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
WO2011098394A2 (en) * 2010-02-09 2011-08-18 Reiner Rittinghausen Composition for the treatment and prevention of anxiety disorders and dyssomnia
AU2011218009B2 (en) 2010-02-17 2016-11-03 Ironwood Pharmaceuticals, Inc Treatments for gastrointestinal disorders
US8828453B2 (en) * 2010-04-29 2014-09-09 Betul Hatipoglu Herbal-based compositions for alleviating symptoms associated with autism
WO2012003181A2 (en) * 2010-07-02 2012-01-05 Fmc Corporation Solid forms
PL2603232T3 (en) 2010-08-11 2020-05-18 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
US9532952B2 (en) * 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
EP2675297A4 (en) * 2011-02-16 2014-10-01 Wellbemed Sweden Ab Foodstuff comprising an extract mixture
WO2012143403A1 (en) * 2011-04-18 2012-10-26 Nestec S.A. Nutritional compositions having alpha-hica and citrulline
UA113291C2 (en) 2011-08-04 2017-01-10 TRANSCLOMYPHENE METABOLITES AND THEIR APPLICATIONS
EP2776055B1 (en) 2011-08-17 2016-12-14 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
ITUD20110196A1 (en) 2011-12-02 2013-06-03 Asoltech S R L COMPOSITION BASED ON UBIDECARENONE
NZ704679A (en) * 2012-08-21 2016-02-26 Repros Therapeutics Inc Trans-clomiphene formulations and uses thereof
MX2015005160A (en) 2012-11-02 2015-07-17 Repros Therapeutics Inc Trans-clomiphene for use in cancer therapy.
EP2926669B1 (en) * 2014-04-02 2017-05-24 AlzChem AG Creatine protein matrix and method for manufacturing the same
MX2016014405A (en) * 2014-05-05 2017-01-20 Boehringer Ingelheim Int Fast dissolving granulate.
PL2974733T3 (en) * 2014-07-14 2017-09-29 Dr. Willmar Schwabe Gmbh & Co. Kg Combination of valerian root extract and lavender oil for use in the treatment of sleep disorders
US9968567B2 (en) 2014-11-14 2018-05-15 Asoltech S.R.L. Composition based on COQ10
AU2016297986B8 (en) 2015-07-29 2020-06-11 Advanced Bionutrition Corp. Stable dry probiotic compositions for special dietary uses
EP3368498A4 (en) 2015-10-27 2019-06-12 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
US10674746B2 (en) 2015-10-27 2020-06-09 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
CN106674057A (en) * 2015-11-09 2017-05-17 江西乐维生物药业有限公司 L-arginine alpha-ketoisocaproate preparation method
WO2017109300A1 (en) * 2015-12-22 2017-06-29 Urgo Recherche Innovation Et Developpement Combination product that helps relax and fall asleep
CA3023305A1 (en) * 2016-05-06 2017-11-09 Physician's Seal, LLC Valerian composition and related methods
JP7007798B2 (en) * 2016-09-13 2022-02-10 オリザ油化株式会社 Circadian rhythm improver
JP6909569B2 (en) * 2016-09-16 2021-07-28 オリザ油化株式会社 Skin quality improver
ES2684414B1 (en) * 2017-03-31 2019-12-11 Laboratorios Vinas S A Galenic composition, for oral use, comprising micronized melatonin and a zinc salt and corresponding method and use
EP3641759B1 (en) 2017-06-20 2024-04-03 Société des Produits Nestlé S.A. Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
JP2020525549A (en) * 2017-06-27 2020-08-27 ハーモニクス エルエルシー Sustained-release sleep aid system
JP6837700B2 (en) 2017-09-08 2021-03-03 インシグニス セラピュティクス, インコーポレイテッドInsignis Therapeutics, Inc. How to use dipivefrine
US10639340B2 (en) * 2018-06-18 2020-05-05 Eric Young Method of drying botanicals
KR102154074B1 (en) 2018-10-17 2020-09-09 한국 한의학 연구원 Composition for preventing, ameliorating or treating sleep disturbance comprising flavonoid compound as effective component
CN110876691A (en) * 2019-10-29 2020-03-13 广东润和生物科技有限公司 Coenzyme Q10Sleep-aiding skin-beautifying massage emulsion
CN113133307A (en) 2019-10-31 2021-07-16 马克一创新中心有限公司 Composition comprising mulberry extract and method for producing the same
US20210299166A1 (en) * 2020-03-25 2021-09-30 Allgood Beverage Company Compositions for maintaining electrolyte balance and urinary tract health
EP4255399A1 (en) * 2020-12-01 2023-10-11 Seattle Gummy Company Ped5 inhibitor semi-solid compositions and methods of making and using thereof
US20220347119A1 (en) * 2021-04-30 2022-11-03 Reshma N. Kheraj Medicated drink
US11833182B2 (en) 2021-08-10 2023-12-05 Shaklee Corporation Sleep product
CN114027508A (en) * 2021-12-03 2022-02-11 龙岩学院 Functional food gamma-aminobutyric acid compound preparation for improving sleep
WO2023107990A1 (en) * 2021-12-08 2023-06-15 Nutramax Laboratories, Inc. Supplemental coating and related method
DE102022114966A1 (en) 2022-06-14 2023-12-14 Alzchem Trostberg Gmbh Water-soluble creatine agglomerate
CN115381890A (en) * 2022-08-01 2022-11-25 澳美制药(苏州)有限公司 Sleep-aiding sustained-release tablet and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050008678A1 (en) * 1996-05-31 2005-01-13 Howard Alan N. Food compositions containing creatine
US6903136B2 (en) * 2002-04-22 2005-06-07 Experimental And Applied Sciences, Inc. Food supplements containing 4-hydroxyisoleucine and creatine
US20050192183A1 (en) * 2004-03-01 2005-09-01 Thomas Gastner Use of guanidine compounds as physiological strengthening agents in the form of nutritional supplements, animal feed additives, in cosmetic preparations and as plant stimulants
US6946151B2 (en) * 2002-11-12 2005-09-20 Ayurvedic-Life International, Llc Therapeutic compositions
US7129273B2 (en) * 2003-04-30 2006-10-31 Creative Compounds, Llc Dicreatine Malate

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4006025A (en) * 1975-06-06 1977-02-01 Polaroid Corporation Process for dispersing sensitizing dyes
US4294917A (en) * 1979-05-22 1981-10-13 Ciba-Geigy Ag Photographic silver halide material containing a dye filter or a dye anti-halation layer
US4294916A (en) * 1979-05-22 1981-10-13 Ciba-Geigy Ag Photographic silver halide material containing a dye filter or a dye anti-halation layer
GB2057420B (en) * 1979-08-30 1984-05-10 Standard Telephones Cables Ltd Controlled release glass
US4490654A (en) * 1983-06-10 1984-12-25 The Arthur G. Russell Company, Incorporated Control circuit for vibratory devices
US4781925A (en) * 1986-03-06 1988-11-01 American Home Products Corporation Calcium supplement compressed tablets
US5520932A (en) * 1988-06-24 1996-05-28 The Upjohn Company Fine-milled colestipol hydrochloride
US4927744A (en) * 1988-08-05 1990-05-22 Eastman Kodak Company Photographic element having solid particle dispersion oxidized developer scavenger
US4950586A (en) * 1988-12-23 1990-08-21 Eastman Kodak Company Solid particle dispersions of filter dyes for photographic elements
US5242941A (en) * 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
HUT62477A (en) * 1991-10-07 1993-05-28 Sandor Milesz Herb mixture
GB9215746D0 (en) * 1992-07-24 1992-09-09 Hultman Eric A method of increasing creatine supply depot
US5449683A (en) 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
EP0616841B1 (en) * 1992-10-09 1998-12-23 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Production method for fine granulate
ES2236700T3 (en) * 1993-11-19 2005-07-16 Janssen Pharmaceutica N.V. 1,2-MICROENCAPSULATED BENZAZOLS.
IT1271687B (en) * 1994-08-04 1997-06-04 Flamma Spa WATER SOLUBLE ORGANIC SALTS OF CREATINE
JPH07252148A (en) * 1994-10-08 1995-10-03 Masahiro Nagahama Therapeutic agent for diabetes
US5726146A (en) * 1994-12-06 1998-03-10 Natural Supplement Association, Incorporated Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass
GB9517443D0 (en) * 1994-12-17 1995-10-25 Univ Nottingham Increasing creatine and glycogen concentration in muscle
US5541801A (en) * 1995-05-26 1996-07-30 United Microelectronics Corporation Low-voltage gate trigger SCR (LVGTSCR) ESD protection circuit for input and output pads
US5681578A (en) * 1996-01-22 1997-10-28 Sahley; Billie J. Composition for relieving stress anxiety, grief, and depression
NZ330739A (en) * 1996-05-20 1999-06-29 Janssen Pharmaceutica Nv Particulate solid dispersion of itraconazole and a water soluble polymer
GB9611356D0 (en) * 1996-05-31 1996-08-07 Howard Alan N Improvements in or relating to compositions containing Creatine, and other ergogenic compounds
US6361794B1 (en) * 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
US6080410A (en) * 1997-03-17 2000-06-27 Natrol, Inc. Method for reducing daily stress and anxiety in adults
US6726133B2 (en) * 1997-07-18 2004-04-27 Pulsewave Llc Process for micronizing materials
US6100287A (en) * 1997-11-13 2000-08-08 University Of Florida Materials and methods for enhancing muscle performance and recovery from fatigue
US5955107A (en) * 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
US6905707B2 (en) * 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
CA2246014C (en) * 1998-08-21 2001-12-11 Paul T. Gardiner Food supplements and methods comprising lipoic acid and creatine
US6136339A (en) * 1998-08-21 2000-10-24 Gardiner; Paul T. Food supplements and methods comprising lipoic acid and creatine
US6599530B2 (en) * 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
FR2789997B1 (en) * 1999-02-18 2004-12-03 Rhodia Chimie Sa COMPOSITION COMPRISING AN OIL IN WATER EMULSION AND AN INORGANIC AGENT
US6383527B1 (en) * 1999-03-04 2002-05-07 Nps Pharmaceuticals, Inc. Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID
US6245352B1 (en) * 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
US9486429B2 (en) * 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
US6869622B2 (en) * 1999-07-21 2005-03-22 Ancile Pharmaceuticals, Inc. Composition for improving sleep quality and efficiency, and methods of preparing and using the composition
US6653352B2 (en) * 1999-09-29 2003-11-25 Medical Merchandising, Inc. Pain reliever and method of use
US6312736B1 (en) * 1999-12-09 2001-11-06 Biotech Corporation Herbal composition to relieve pain
US20010041675A1 (en) * 2000-01-24 2001-11-15 Jacobs Robert H. Satisfy composition and method of weight control
US20020076437A1 (en) * 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
US6399116B1 (en) * 2000-04-28 2002-06-04 Rulin Xiu Rhodiola and used thereof
AU5967101A (en) * 2000-05-10 2001-11-20 Rtp Pharma Inc Media milling
US6277396B1 (en) * 2000-05-11 2001-08-21 Maximum Human Performance, Inc. Dietary supplement containing a thermogenic substance and an adrenal support substance
AU8847101A (en) * 2000-08-31 2002-03-13 Rtp Pharma Inc Milled particles
AUPR177300A0 (en) * 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
US20050129783A1 (en) * 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
JP2002371003A (en) * 2001-06-15 2002-12-26 Kikkoman Corp Inhibitor against blood sugar level increase
US20030013639A1 (en) * 2001-07-03 2003-01-16 Lisa Yurchak Sleep inducing antacid composition
CN1625406A (en) * 2001-08-09 2005-06-08 底古萨食品配料有限公司 Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals
EP1446135B1 (en) * 2001-09-17 2007-07-25 Phytos Inc. Standardized extracts of scutellaria lateriflora
US6770263B1 (en) * 2001-10-01 2004-08-03 Naturewell, Incorporated Compositions and methods for the treatment of aches and pains
US6579543B1 (en) * 2002-02-22 2003-06-17 Jackie H. McClung Composition for topical application to skin
DE10208335A1 (en) * 2002-02-27 2003-09-04 Roehm Gmbh Pharmaceutical form and process for its preparation
WO2003082241A2 (en) * 2002-04-03 2003-10-09 Ranbaxy Laboratories Limited Clarithromycin formulations having improved bioavailability
US20030232091A1 (en) * 2002-06-17 2003-12-18 Adi Shefer Stabilized retinol for cosmetic dermatological, and pharmaceutical compositions, and use thereof
US20040005368A1 (en) * 2002-07-01 2004-01-08 Morris Mann Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite
US7625362B2 (en) * 2003-09-16 2009-12-01 Boehringer Technologies, L.P. Apparatus and method for suction-assisted wound healing
US6703412B1 (en) * 2002-09-27 2004-03-09 Holly A. Rosenthal Method of treating sleeplessness with melatonin on an acute basis
AU2003283004A1 (en) * 2002-10-22 2004-05-13 Waratah Pharmaceuticals, Inc. Treatment of diabetes
EP1562555A2 (en) * 2002-10-24 2005-08-17 Enos Pharmaceuticals, Inc. Sustained release l-arginine formulations and methods of manufacture and use
US20040247699A1 (en) * 2002-12-20 2004-12-09 Bernardina Johanna Martina Delsing Method for the prevention or treatment of overweight in mammals
JP2004217532A (en) * 2003-01-10 2004-08-05 Maruzen Pharmaceut Co Ltd Mulberry leaf extract and method for producing the same, and anti-hyperglycemic composition and obesity-preventing composition
WO2004073632A2 (en) * 2003-02-19 2004-09-02 Biovail Laboratories Inc. Rapid absorption selective 5-ht agonist formulations
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
CN1257259C (en) * 2003-06-21 2006-05-24 陈豪锋 Formulation for health-care red rice wine
EP1686976A2 (en) * 2003-11-05 2006-08-09 Santarus, Inc. Combination of proton pump inhibitor and sleep aid
ES2366646T3 (en) * 2003-11-05 2011-10-24 Elan Pharma International Limited COMPOSITIONS IN THE FORM OF NANOPARTICLES THAT HAVE A PEPTIDE AS A SURFACE STABILIZER.
DE10352822A1 (en) * 2003-11-12 2005-06-23 Bioghurt Biogarde Gmbh & Co. Kg Use of an additionally fermented cereal sludge for the prevention and / or treatment of elevated blood sugar levels
US8337915B2 (en) * 2004-01-10 2012-12-25 S George Aburdeineh Fenugreek seed extract to lower blood cholesterol
MXPA06009377A (en) * 2004-02-20 2007-03-07 Lifescape Biosciences Inc Compositions and methods for sleep regulation.
DE102004008804A1 (en) * 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Multilayer tablet
BRPI0506793A (en) * 2004-02-20 2007-05-22 Rinat Neuroscience Corp Obesity or diabetes treatment methods using nt-4/5
ATE477809T1 (en) * 2004-04-06 2010-09-15 Taiyokagaku Co Ltd USE OF A COMBINATION OF THEANINE AND SEROTONIN FOR SLEEP DISORDER
CN1568803A (en) * 2004-04-30 2005-01-26 南阳市海达生物技术有限公司 Food with blood-sugar/blood-fat reducing function and preparation method thereof
US20050249843A1 (en) * 2004-05-07 2005-11-10 Loren Wallis Low carbohydrate caramel corn composition
US20050282870A1 (en) * 2004-06-16 2005-12-22 Carter Stephen G Peripherally-acting vasodilators
DE102004036047A1 (en) * 2004-07-24 2006-02-23 Bioghurt Biogarde Gmbh & Co. Kg Physiologically active composition
CA2577963C (en) * 2004-08-25 2015-10-06 Mtor Formulations Ltd. Compositions and methods for activating protein synthesis and deactivating catabolic processes in skeletal muscle
US20060083793A1 (en) * 2004-09-29 2006-04-20 Gardiner Paul T Nutritional composition for promoting muscle performance and acting as hydrogen (H+) blocker
EP1871183A4 (en) * 2005-04-11 2008-06-11 New Cell Formulations Ltd Supplemental dietary composition for increasing muscle size and strength
CA2516678A1 (en) * 2005-08-18 2007-02-18 Gakic Formulations Ltd. Supplemental dietary composition for enhancing muscle performance and/or recovery from fatigue

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050008678A1 (en) * 1996-05-31 2005-01-13 Howard Alan N. Food compositions containing creatine
US6903136B2 (en) * 2002-04-22 2005-06-07 Experimental And Applied Sciences, Inc. Food supplements containing 4-hydroxyisoleucine and creatine
US6946151B2 (en) * 2002-11-12 2005-09-20 Ayurvedic-Life International, Llc Therapeutic compositions
US7129273B2 (en) * 2003-04-30 2006-10-31 Creative Compounds, Llc Dicreatine Malate
US20050192183A1 (en) * 2004-03-01 2005-09-01 Thomas Gastner Use of guanidine compounds as physiological strengthening agents in the form of nutritional supplements, animal feed additives, in cosmetic preparations and as plant stimulants

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10869843B2 (en) 2010-11-23 2020-12-22 Chemi Nutra Method for increasing muscle mass and strength
WO2015050809A1 (en) * 2013-10-01 2015-04-09 Novozymes A/S Processes of producing fermentation products

Also Published As

Publication number Publication date
CA2556305A1 (en) 2007-08-23
CA2642761A1 (en) 2007-08-30
US20070202166A1 (en) 2007-08-30
US7914826B2 (en) 2011-03-29
CA2556305C (en) 2013-08-06
ZA200807489B (en) 2009-11-25
WO2007095716A1 (en) 2007-08-30
CA2560107C (en) 2016-03-29
WO2007095733A1 (en) 2007-08-30
EP1996199A1 (en) 2008-12-03
EP1991241A1 (en) 2008-11-19
US20070196470A1 (en) 2007-08-23
AU2006338839A1 (en) 2007-08-30
WO2007095734A1 (en) 2007-08-30
WO2007095718A1 (en) 2007-08-30
US7749547B2 (en) 2010-07-06
CA2560107A1 (en) 2007-08-23
JP2009527504A (en) 2009-07-30
US7794749B2 (en) 2010-09-14
US7476405B2 (en) 2009-01-13
EP1996199A4 (en) 2009-07-15
US20070196348A1 (en) 2007-08-23
US20070202165A1 (en) 2007-08-30
US20070196508A1 (en) 2007-08-23
EP1991241A4 (en) 2009-07-08
US20070264337A1 (en) 2007-11-15
AU2006338840A1 (en) 2007-08-30
US7906154B2 (en) 2011-03-15
US20090011015A1 (en) 2009-01-08
WO2007095717A1 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
US20090142410A1 (en) Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise
CA2566343C (en) Nutritional composition for increasing creatine uptake in skeletal muscle
JP5830030B2 (en) Low calorie high protein nutritional composition for stimulating muscle protein synthesis
US20070015686A1 (en) Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells
HUE031760T2 (en) Dietary supplements containing extracts of cinnamon and methods of using same to enhance creatine transport
KR20040044455A (en) Nutritional compositions for controlling blood glucose level
KR20200039748A (en) Amino acid composition for treatment of liver disease
MX2010009015A (en) Leaves extract of panax sp., a process of making the same and uses thereof.
US11266668B2 (en) Dietary supplement for glycemia control and diabetes prevention
EP2303040A1 (en) Synergistic enhancement of cellular ergogenic nutrient uptake, like creatine or carnitine, with tarragon
US20160015777A1 (en) Protein Delivery System and Method of Making Same
US10757961B2 (en) Dietary supplement for glycemia control and diabetes prevention
US7416750B1 (en) Composition to provide maintenance and nutritional support in glycemic control deficits
CN112715961A (en) Food composition for promoting muscle growth of elderly diabetic patients
EP3235510A1 (en) Nutritional compositions for the management of glucose metabolism
US20080095865A1 (en) Composition and method for increasing lean muscle mass, decreasing muscle loss, increasing muscle strength and improving athletic performance
AU5778801A (en) Improvements in effervescent tablet manufacture
Shukla INSULIKE Tablets: A Phenotypic Nutrition for Natural Sugar Balance
CN117715634A (en) Composition comprising a mixture of compounds and use thereof
US20210346334A1 (en) Nutritional chromium compositions and methods of use
AU2019305075A1 (en) Nutritional compositions for enhancement of muscle performance
ZA200609169B (en) Nutritional composition for increasing creatine uptake in skeletal muscle

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION